Inventiv Health (VTIV) 10-Q 13 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 10, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Trading Symbol	VTIV
Entity Registrant Name	INVENTIV HEALTH INC
Entity Central Index Key	1,089,473
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		1,000

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 77,113	$ 121,317
Restricted cash	2,554	1,607
Accounts receivable, net of allowances for doubtful accounts of $5,368 and $5,395 at March 31, 2016 and December 31, 2015, respectively	328,326	359,081
Unbilled services	261,723	207,465
Prepaid expenses and other current assets	45,059	42,930
Income tax receivable	1,022	1,076
Total current assets	715,797	733,476
Property and equipment, net	139,172	142,032
Goodwill	896,765	895,369
Intangible assets, net	325,919	334,646
Non-current deferred tax assets	10,421	10,032
Other assets	39,721	37,134
Total assets	2,127,795	2,152,689
Current liabilities:
Current portion of capital lease obligations and other financing arrangements	25,296	23,333
Accrued payroll, accounts payable and accrued expenses	318,948	333,726
Income taxes payable	3,829	5,484
Deferred revenue and client advances	246,621	246,656
Total current liabilities	594,694	609,199
Capital lease obligations, net of current portion	45,525	45,258
Long-term debt, net of current portion	2,117,132	2,101,885
Non-current income tax liability	7,567	5,942
Deferred tax liability	79,106	73,360
Other non-current liabilities	66,750	88,153
Total liabilities	$ 2,910,774	$ 2,923,797
Commitments and contingencies (Note 7)
inVentiv Health, Inc. stockholder’s deficit:
Common stock, $.01 par value, 1,000 shares authorized, issued and outstanding at March 31, 2016 and December 31, 2015, respectively	$ 1	$ 1
Additional paid-in-capital	575,156	573,739
Accumulated deficit	(1,328,213)	(1,309,136)
Accumulated other comprehensive loss	(31,921)	(37,340)
Total inVentiv Health, Inc. stockholder’s deficit	(784,977)	(772,736)
Noncontrolling interest	1,998	1,628
Total stockholder’s deficit	(782,979)	(771,108)
Total liabilities and stockholder’s deficit	$ 2,127,795	$ 2,152,689

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Allowances for doubtful accounts	$ 5,368	$ 5,395
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	1,000	1,000
Common stock, shares issued	1,000	1,000
Common stock, shares outstanding	1,000	1,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Net revenues	$ 541,296	$ 450,977
Reimbursed out-of-pocket expenses	90,983	67,323
Total revenues	632,279	518,300
Operating expenses:
Cost of revenues	372,376	300,505
Reimbursable out-of-pocket expenses	90,983	67,323
Selling, general and administrative expenses	123,756	132,914
Total operating expenses	587,115	500,742
Operating income (loss)	45,164	17,558
Gain on extinguishment of debt	221
Interest expense	(55,917)	(56,479)
Interest income	64	16
Income (loss) before income tax (provision) benefit and income (loss) from equity investments	(10,468)	(38,905)
Income tax (provision) benefit	(8,176)	(4,528)
Income (loss) before income (loss) from equity investments	(18,644)	(43,433)
Income (loss) from equity investments	5	(1,529)
Net income (loss)	(18,639)	(44,962)
Less: Net (income) loss attributable to the noncontrolling interest	(438)	(123)
Net income (loss) attributable to inVentiv Health, Inc.	$ (19,077)	$ (45,085)

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net Income (loss)	$ (18,639)	$ (44,962)
Other comprehensive income (loss):
Foreign currency translation adjustment	5,419	(5,445)
Total other comprehensive income (loss)	5,419	(5,445)
Total comprehensive income (loss)	(13,220)	(50,407)
Less: Comprehensive (income) loss attributable to the noncontrolling interest	(438)	(123)
Comprehensive income (loss) attributable to inVentiv Health, Inc.	$ (13,658)	$ (50,530)

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Stockholder's Deficit - 3 months ended Mar. 31, 2016 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Non- controlling Interest [Member]
Beginning Balance, Amount at Dec. 31, 2015	$ (771,108)	$ 1	$ 573,739	$ (1,309,136)	$ (37,340)	$ 1,628
Beginning Balance, Shares at Dec. 31, 2015	1,000	1,000
Net loss	$ (18,639)			(19,077)		438
Foreign currency translation adjustment	5,419				5,419
Stock-based compensation expense	1,417		1,417
Distributions to noncontrolling interest	(68)					(68)
Ending Balance, Amount at Mar. 31, 2016	$ (782,979)	$ 1	$ 575,156	$ (1,328,213)	$ (31,921)	$ 1,998
Ending Balance, Shares at Mar. 31, 2016	1,000	1,000

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net Income (loss)	$ (18,639)	$ (44,962)
Adjustments to reconcile net income (loss) to net cash provided by (used) in operating activities:
Depreciation	14,646	11,263
Amortization of intangible assets	9,117	13,740
Amortization of deferred financing costs and original issue discount/premium	4,723	4,751
Payment-in-kind interest	8,025	15,677
(Gain) loss on disposal of assets	447	557
Stock-based compensation expense	1,417	470
Gain on extinguishment of debt	(221)
Deferred taxes	5,736	2,988
Other non-cash adjustments	803	2,509
Changes in assets and liabilities, net
Accounts receivable, net	31,171	(6,235)
Unbilled services	(53,822)	(21,522)
Prepaid expenses and other current assets	(364)	(2,394)
Accrued payroll, accounts payable and accrued expenses	(11,910)	9,329
Income tax receivable and non-current income tax liability	(202)	1,103
Deferred revenue and client advances	2,355	16,898
Other, net	(2,902)	(2,021)
Net cash provided by (used in) operating activities	(9,620)	2,151
Cash flows from investing activities:
Purchases of property and equipment	(6,170)	(9,799)
Proceeds from vehicle sales and rebates on vehicle leases	3,979	3,093
Other, net	(966)	(238)
Net cash provided by (used in) investing activities	(3,157)	(6,944)
Cash flows from financing activities:
Repayments on capital leases and other financing arrangements	(8,907)	(8,924)
Repurchase of Notes	(22,790)
Borrowings under line of credit		17,000
Repayment on line of credit		(17,000)
Payment on installment note and contingent consideration related to acquisition	(2,174)	(1,917)
Other, net	396	25
Net cash provided by (used in) financing activities	(33,475)	(10,816)
Effects of foreign currency exchange rate changes on cash	2,048	(2,797)
Net increase (decrease) in cash and cash equivalents	(44,204)	(18,406)
Cash and cash equivalents, beginning of period	121,317	57,059
Cash and cash equivalents, end of period	77,113	38,653
Supplemental disclosure of cash flow information:
Cash paid for interest	31,281	32,888
Cash paid (refund) for income taxes	2,714	526
Supplemental disclosure of non-cash activities:
Vehicles acquired through capital lease agreements	10,667	12,436
Accrued capital expenditures	$ 884	$ 2,487

Organization and Business

Organization and Business	3 Months Ended
	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Business	1. Organization and Business inVentiv Health, Inc. (“inVentiv”, or the “Company”) is a leading global provider of outsourced clinical development and commercialization services to biopharmaceutical companies. The Company provides services through two reportable business segments: Clinical and Commercial. The Company provides a full suite of services to enhance its clients’ ability to successfully develop, launch and market their products. The Company offers its solutions on both a standalone and integrated basis. The Company’s services cover the entire biopharmaceutical development and commercialization continuum spanning from first-in-human clinical trials to the ongoing commercialization of mature products. On August 4, 2010, inVentiv Acquisition, Inc., an indirect, wholly owned subsidiary of inVentiv Group Holdings, Inc. (“Group Holdings” or “Parent”) merged with and into the Company (the “THL Acquisition”). Group Holdings is controlled by affiliates of Thomas H. Lee Partners (“THL”), a global private investment and advisory firm, as well as certain co-investors and certain members of management (together with the private equity funds sponsored by THL, and the co-investors, the “Investors”).

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	2. Basis of Presentation The unaudited condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), and include the accounts of inVentiv Health, Inc. and its wholly owned subsidiaries. In addition, the Company consolidates the accounts of its 60% owned subsidiary and reflects the minority interest as a noncontrolling interest classified in equity. The Company has both equity and cost method investments in securities of certain privately held entities. Investments accounted for under the equity method are recorded at the amount of the Company’s investment and adjusted each period for the Company’s share of the investee’s income or loss. During the quarter ended March 31, 2015, the Company recognized a $1.6 million loss on dissolution of a joint venture accounted for under the equity method, which is included in income (loss) from equity investments in the consolidated statements of operations. Investments accounted for under the cost method are recorded at the historical carrying value. The carrying value of both types of investments is recorded in other assets in the consolidated balance sheets and is immaterial. All intercompany transactions have been eliminated in consolidation. The condensed consolidated financial statements as of March 31, 2016 and for the three months ended March 31, 2016 and 2015 are unaudited, but in the opinion of management include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the results for the interim periods. They do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the 2015 audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 dated March 18, 2016 on file with the Securities and Exchange Commission (the “SEC”). The results reported in these condensed consolidated financial statements should not necessarily be viewed as indicative of the results that may be expected for the entire year. The balance sheet at December 31, 2015 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited condensed consolidated financial statements of the Company have been prepared in conformity with GAAP, which requires management to make estimates and judgments that affect the reported amount of assets, liabilities, revenue, and expenses and disclosure of contingent assets and liabilities in the accompanying financial statements. The significant estimates made by the Company include the estimated forecast that is used in assessing the realizability of the Company’s deferred tax assets and assessing whether the fair value of intangible assets and goodwill exceed the related carrying value. In addition, the Company also makes significant estimates as it relates to revenue recognition, self-insurance reserves, including reserves for employee medical, automobile insurance and worker’s compensation. In the opinion of management, all adjustments considered necessary for a fair presentation have been reflected in these unaudited condensed consolidated financial statements. Reclassifications In the Company’s 2015 financial statements, the Company reclassified certain costs from selling, general and administrative (“SG&A”) expenses to cost of revenues to conform to the presentation adopted for 2015. The revised classification aligns all personnel and related costs associated with service delivery within cost of revenues, along with the associated information technology costs supporting these processes. These changes better harmonize the accounting policies of the group, and are consistent with how management is assessing performance and managing costs. As a result of the revision in the classification of the costs, the previously reported SG&A was reduced by $9.3 million for the three months ended March 31, 2015, and cost of revenues has increased by a corresponding amount. The reclassification had no impact on our consolidated financial position, net operating results included in our statements of operations or cash flows.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2016
Recent Accounting Pronouncements [Abstract]
Recent Accounting Pronouncements	3. Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2016-09 (“ASU 2016-09”), Compensation—Stock Compensation In February 2016, the FASB issued ASU 2016-02, Leases In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers

Goodwill

Goodwill	3 Months Ended
	Mar. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	4. Goodwill The following table sets forth the carrying amount of goodwill for each segment as of March 31, 2016 and December 31, 2015 (in thousands): Clinical Commercial Total Net goodwill at December 31, 2015 $ 382,215 $ 513,154 $ 895,369 Foreign currency translation (1 ) 1,397 1,396 Net goodwill at March 31, 2016 $ 382,214 $ 514,551 $ 896,765 As of March 31, 2016 and December 31, 2015, the Company had accumulated goodwill impairment losses of $478.3 million.

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets	5. Intangible Assets The following table sets forth the carrying amount of the Company’s intangible assets as of March 31, 2016 and December 31, 2015 (in thousands): March 31, 2016 December 31, 2015 Accumulated Accumulated Gross Amortization Net Gross Amortization Net Customer relationships $ 366,169 $ (156,458 ) $ 209,711 $ 365,777 $ (148,679 ) $ 217,098 Technology 27,090 (26,364 ) 726 27,003 (26,206 ) 797 Tradenames subject to amortization 18,314 (16,787 ) 1,527 18,293 (16,657 ) 1,636 Backlog 95,029 (90,783 ) 4,246 95,014 (89,427 ) 5,587 Other 1,020 (615 ) 405 1,020 (585 ) 435 Total finite-lived intangible assets 507,622 (291,007 ) 216,615 507,107 (281,554 ) 225,553 Tradenames not subject to amortization 109,304 — 109,304 109,093 — 109,093 Total intangible assets $ 616,926 $ (291,007 ) $ 325,919 $ 616,200 $ (281,554 ) $ 334,646

Debt

Debt	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Debt	6. Debt The Company’s indebtedness is summarized as follows (in thousands): March 31, December 31, 2016 2015 Senior Secured Credit Facilities: Term Loan Facility B3 loans, due 2018 $ 129,645 $ 129,645 Term Loan Facility B4 loans, due 2018 445,694 445,694 Senior Secured Notes, due 2018 625,000 625,000 ABL Facility — — Junior Lien Secured Notes, due 2018 579,837 569,691 Senior Unsecured Notes, due 2018 376,316 376,316 International Facility — — Capital leases and other financing arrangements 70,821 68,591 Total borrowings 2,227,313 2,214,937 Less: unamortized premium (discount) (7,993 ) (9,030 ) Less: unamortized deferred financing costs (31,367 ) (35,431 ) Less: current portion of capital leases and other financing arrangements (25,296 ) (23,333 ) Total long-term borrowings, net of current portion $ 2,162,657 $ 2,147,143 At March 31, 2016, the Company had $575.3 million outstanding under the Senior Secured Credit Facilities, which consisted of $129.6 million under the B3 term loans and $445.7 million under the B4 term loans. The Company had $625.0 million outstanding under the Senior Secured Notes, and there were no outstanding borrowings under the ABL Facility (as defined below). The Company also had $579.8 million outstanding under the Junior Lien Secured Notes (as defined below), and $376.3 million outstanding under the Senior Unsecured Notes. In addition, the Company had capitalized leases and other financing arrangements of $70.8 million outstanding as of March 31, 2016. On July 1, 2015 one of the Company’s indirect subsidiaries in the United Kingdom, inVentiv Health Clinical UK Ltd., (“inVentiv UK”) as borrower, and one of the Company’s indirect subsidiaries in Switzerland, inVentiv Health Switzerland GmbH, as guarantor, entered into an asset-based lending facility (the “International Facility”) for up to $20.0 million. This facility is available to enhance international cash management. At March 31, 2016, the Company had no outstanding borrowings under the International Facility and would have been able to borrow up to $14.9 million. On August 15, 2014, the Company consummated an exchange offer (the “Junior Lien Notes Exchange Offer”) with holders of its 10% Senior Unsecured Notes due 2018 in which the Company issued $475.0 million aggregate principal amount of new 10%/12% Junior Lien Secured Notes due 2018 (the “Junior Lien Secured Notes”) in exchange for a like amount of the Company’s 10% Senior Unsecured Notes due 2018. The Junior Lien Secured Notes permit up to six semi-annual interest payments to be settled through the issuance of additional Junior Lien Secured Notes. The interest rate with respect to the Junior Lien Secured Notes is a cash rate of 10% per annum or a payment-in-kind (“PIK”) rate of 12% per annum (“PIK Interest”). The Company paid interest on the Junior Lien Secured Notes for the periods commencing August 15, 2014, February 15, 2015 and August 15, 2015 in PIK Interest and elected to pay interest for the period commencing February 15, 2016 in cash. On January 8, 2016, the Company’s Board of Directors approved the repurchase by the Company of its certain Junior Lien Secured Notes and the subsequent cancellation of such repurchased notes (the “PIK Note Repurchase”). During the three months ended March 31, 2016, the Company repurchased and cancelled an aggregate principal amount of $23.7 million of its Junior Lien Secured Notes, including accrued and unpaid interest, through open market purchases for $23.1 million. As a result of the PIK Note Repurchase, the Company reduced its debt and a pro rata portion of deferred financing costs and debt discount on the transactions and recorded a gain on extinguishment of debt of $0.2 million. On August 12, 2014, in connection with the Junior Lien Notes Exchange Offer, affiliates of Thomas H. Lee Partners, L.P. and certain co-investors purchased $25.0 million of Junior Lien Secured Notes and $26.3 million of the Company’s 10% Senior Unsecured Notes due 2018 for a total consideration of $50.0 million (the “New Money Investment”). The $26.3 million of 10% Senior Unsecured Notes due 2018 were issued at a 5% discount to par value resulting in a $1.3 million discount that is accreted over the related term using the effective interest method. Additionally, on August 15, 2014 the Company issued an additional $7.0 million of Junior Lien Secured Notes (the “Backstop Consideration”) to a group of holders of the Company’s 10% Senior Unsecured Notes due 2018 as consideration for such holders’ agreement to tender the 10% Senior Unsecured Notes due 2018 held by them into the Junior Lien Notes Exchange Offer. In connection with the Junior Lien Notes Exchange Offer, the Company’s term loan facility and asset-backed revolving facility were amended on July 28, 2014 (the “Credit Agreement Amendments”) to permit the Junior Lien Notes Exchange Offer, the New Money Investment and the issuance of the Backstop Consideration and to extend the maturities of certain outstanding term loans from 2016 to 2018. The margin on the term loans increased by 0.25% when compared to the interest rates on the prior term loans. There was no net change in the outstanding principal balance of the term loans as a result of the modified terms. On August 16, 2013, the Company, Citibank, N.A. and certain financial institutions entered into a credit agreement for an asset-based revolving credit facility of up to $150.0 million (the “ABL Facility”), subject to borrowing base availability, which matures on August 16, 2018. Up to $35.0 million of the ABL Facility is available for the issuance of letters of credit. All obligations under the ABL Facility are secured by the Company’s domestic subsidiaries and secured by a first priority lien on current assets of the Company and its domestic subsidiaries and a second priority lien on all other assets of the Company and its domestic subsidiaries. The available borrowing capacity varies monthly according to the levels of the Company’s eligible accounts receivable and unbilled receivables. As of March 31, 2016, the Company had no outstanding borrowings under the ABL Facility, approximately $18.8 million in letters of credit outstanding against the ABL Facility and would have been able to borrow up to an additional $131.2 million. Cash Pooling The Company and certain of its international subsidiaries entered into a notional cash pooling arrangement (“Cash Pool”) to help manage global liquidity requirements. The parties to the arrangement combine their cash balances in pooling accounts with the ability to set-off overdrafts to the bank against positive cash balances. Each subsidiary receives interest on the cash balances or pays interest on amounts owed. At March 31, 2016, the Company’s net cash position in the pool of $34.4 million, defined as the gross cash position in the pool of $113.6 million less borrowings of $79.2 million, is reflected as cash and cash equivalents in the consolidated balance sheet. Fair Value of Long-Term Debt The carrying amounts and the estimated fair values of long-term debt as of March 31, 2016 and December 31, 2015 are as follows (in thousands): March 31, 2016 December 31, 2015 Carrying value Estimated fair value Carrying value Estimated fair value Term Loan Facility $ 568,497 $ 573,576 $ 567,673 $ 570,051 Senior Secured Notes 619,410 643,750 618,616 633,594 Junior Lien Secured Notes 564,027 583,461 551,552 537,646 Senior Unsecured Notes 365,197 372,553 364,043 371,142 The fair value of long-term debt instruments is measured based on market values for debt issues with similar characteristics, such as maturities, credit ratings, collateral and interest rates available on the measurement dates for debt with similar terms (level 2 within the fair value hierarchy). The Company believes the carrying values for capital leases and other financing arrangements approximate their fair values.

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Contingencies	7. Contingencies On October 31, 2013, Cel-Sci Corporation (Cel-Sci) (“Claimant”) made a demand for arbitration under a Master Services Agreement (the “MSA”), dated as of April 6, 2010 between Claimant and two of the Company’s subsidiaries, inVentiv Health Clinical, LLC (formerly known as PharmaNet, LLC) and PharmaNet GmbH (currently known as inVentiv Health Switzerland GmbH and formerly known as PharmaNet AG) (collectively, “PharmaNet”). Under the MSA and related project agreement, which were terminated by Claimant in April 2013, Claimant engaged PharmaNet in connection with a Phase III Clinical Trial of its investigational drug. The arbitration claim alleges (i) breach of contract, (ii) fraud in the inducement, and (iii) common law fraud on the part of PharmaNet, and seeks damages of at least $50 million. In December 2013, inVentiv Health Clinical, LLC filed a counterclaim against Claimant that alleges breach of contract and seeks at least $2 million in damages. The matter proceeded to the discovery phase. In January 2015, inVentiv Health Clinical, LLC filed additional counterclaims against Claimant that allege (i) breach of contract, (ii) opportunistic breach, restitution and unjust enrichment, and (iii) defamation, and seeks at least $2 million in damages and $20 million in other equitable remedies. A hearing is currently scheduled to begin in September 2016. No assessment can be made at this time as to the likely outcome of this matter. Accordingly, no provision has been recorded as no loss is considered probable. Other Matters The Company is subject to lawsuits, investigations and claims arising out of the conduct of its business, including those related to commercial transactions, contracts, government regulation and employment matters. Certain claims, suits and complaints have been filed or are pending against the Company. The Company does not believe that the outcome of any legal proceedings, if decided adversely to its interests, would have a material adverse effect on its business, financial condition or results of operations.

Concentration of Credit Risk

Concentration of Credit Risk	3 Months Ended
	Mar. 31, 2016
Risks And Uncertainties [Abstract]
Concentration of Credit Risk	8. Concentration of Credit Risk The Company’s receivables are concentrated with major pharmaceutical companies. Credit risk is managed through the continuous monitoring of exposures with the Company’s clients. The Company does not require collateral or other security to support client receivables. For the three months ended March 31, 2016, one client accounted for approximately 12% of the Company’s net revenues. For the three months ended March 31, 2015, no client represented more than 10% of the Company’s net revenues. As of March 31, 2016, one client represented approximately 10% of the accounts receivable balance.

Common Stock and Stock Incentiv

Common Stock and Stock Incentive Plans	3 Months Ended
	Mar. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Common Stock and Stock Incentive Plans	9. Common Stock and Stock Incentive Plans On July 2, 2015 the Company’s Board of Directors approved the grant of new option awards to eligible employees in exchange for certain outstanding restricted stock units granted under the Group Holdings’ Equity Incentive Plan, on a one-for-one basis. Thirty-five percent of the options in the new award vest upon the passage of time and completion of a service requirement and sixty-five percent vests based upon achievement of certain specified performance targets and completion of a service requirement. Approximately 148,748 of the outstanding restricted stock units were exchanged in the program. The exchange was treated as a modification of the awards and no incremental stock compensation was recognized as the exchange securities were not considered probable of vesting on the date of the exchange. The Company recognizes the fair value of the new option awards in compensation expense over the service period to the extent that vesting of the awards is considered probable. On March 25, 2016, the Company granted 106,218 share-based awards. Of these share-based awards, 102,496 represent options that vest thirty-five percent upon the passage of time and completion of a service requirement and sixty-five percent upon achievement of certain specified performance targets and completion of a service requirement. The remaining 3,722 share-based awards are comprised of restricted stock awards that vest if a liquidity event occurs such that the Investors achieve a defined return on their investment and options that vest based on the passage of time.

Termination Benefits and Other

Termination Benefits and Other Cost Reduction Actions	3 Months Ended
	Mar. 31, 2016
Restructuring And Related Activities [Abstract]
Termination Benefits and Other Cost Reduction Actions	10. Termination Benefits and Other Cost Reduction Actions The Company undertook certain actions to continue to integrate its acquisitions and implement cost containment measures in an effort to better align operating costs with market and business conditions. Expenses related to these actions that include real estate consolidations, elimination of redundant functions and employees, are summarized below (in thousands): For the Three Months Ended March 31, 2016 2015 Employee severance and related costs $ 2,745 $ 2,579 Facilities-related costs 1,385 176 Total $ 4,130 $ 2,755 For the three months ended March 31, 2016 and 2015, restructuring costs of $1.5 million and $1.3 million, respectively, have been included in cost of revenues and $2.6 million and $1.4 million, respectively, have been included in SG&A expenses, respectively. The $4.1 million of costs incurred in the three months ended March 31, 2016 includes $1.2 million of costs related to Clinical and $2.9 million related to Commercial. The $2.8 million of costs incurred in the three months ended March 31, 2015 includes $1.0 million of costs related to Clinical, $1.7 million related to Commercial and $0.1 million related to Corporate. The following table summarizes the Company’s restructuring reserve as of March 31, 2016 and December 31, 2015 (in thousands): Balance at Balance at December March 31, 2015 Net Costs Cash Payments 2016 Employee severance and related costs $ 4,245 $ 2,745 $ (3,115 ) $ 3,875 Facilities-related costs 3,942 1,385 (1,388 ) 3,939 Total $ 8,187 $ 4,130 $ (4,503 ) $ 7,814 The Company expects that severance payments accrued at March 31, 2016 will be paid within the next twelve months. Certain facility costs will be paid over the remaining lease term of the exited facilities through 2027. The net costs in the table above exclude non-cash charges of approximately $0.2 million for the three months ended March 31, 2016 related to abandoned assets at certain facilities.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes The Company accounts for income taxes at each interim period using its estimated annual effective tax rate. Discrete items and changes in the estimate of the annual effective tax rate are recorded in the period they occur. The consolidated effective tax rate was approximately (78.1%) and (11.6%) for the three months ended March 31, 2016 and 2015, respectively. The income tax provision for the three months ended March 31, 2016 and 2015 reflects that the Company (i) continued to record a full valuation allowance for its domestic and certain foreign tax jurisdictions, (ii) recorded a tax provision for certain foreign and state jurisdictions that generated earnings, (iii) incurred a deferred tax provision in its domestic jurisdiction arising from taxable temporary differences related to amortization of indefinite-lived intangible assets and goodwill, and (iv) recorded changes in unrecognized tax benefits (including related penalties and interest) as they occur. The Company provides a valuation allowance to reduce deferred tax assets to their estimated realizable value if, based on the weight of all available evidence, it is not more likely than not that a portion or all of the deferred tax assets will be realized. The Company does not expect to record significant tax benefits on future domestic net operating losses until circumstances justify the recognition of such benefits. As a result of the domestic valuation allowance, taxable temporary differences from the amortization of goodwill and indefinite-lived intangible assets are expected to result in $8.5 million of income tax expense for 2016, and are reflected in the Company’s estimated domestic annual effective tax rate. Goodwill and indefinite-lived intangible assets are amortized for income tax purposes, but not for financial statement reporting purposes. This difference results in net deferred income tax expense since the taxable temporary difference cannot be scheduled to reverse during the loss carryforward period. The Company will record tax expense related to the amortization of its tax deductible goodwill and indefinite-lived intangible assets during those future periods for which it maintains domestic valuation allowances, or until its estimated unamortized balance of $111.4 million at December 31, 2016 is fully amortized for tax purposes.

Related Parties

Related Parties	3 Months Ended
	Mar. 31, 2016
Related Party Transactions [Abstract]
Related Parties	12. Related Parties Management Arrangements Upon completion of the THL Acquisition, the Company entered into a management agreement (“THL Management Agreement”) with THL Managers VI, LLC (“THL Managers”), in which THL Managers agreed to provide management services to the Company until the tenth anniversary of the consummation of the THL Acquisition with evergreen one-year extensions thereafter. Pursuant to the THL Management Agreement, THL Managers will receive an aggregate annual management fee in an amount per year equal to the greater of (a) $2.5 million or (b) 1.5% of EBITDA, as defined in the THL Management Agreement. In addition, the Company will reimburse out-of-pocket expenses, including travel related costs, incurred by THL Managers. The Company recognized $0.9 million and $0.7 million in management fees and related costs for the three months ended March 31, 2016 and 2015, respectively. The management agreement with the THL Managers includes customary exculpation and indemnification provisions in favor of the THL Managers and their affiliates. The THL Managers may terminate their management agreement at any time. The THL Managers’ management agreement will terminate automatically upon an initial public offering or a change of control. Upon termination due to an initial public offering or a change of control, the THL Managers will be entitled to a termination fee based on the net present value of their annual fee due during the remaining period from the date of termination to the then applicable scheduled date of termination of their management agreement. Upon completion of the THL Acquisition, the Company entered into a management agreement with Liberty Lane IH LLC (“Liberty Lane”), in which Liberty Lane agreed to provide management services to the Company. Mr. Meister, the Company’s former Chief Executive Officer, is affiliated with Liberty Lane. Pursuant to the agreement, Liberty Lane or its affiliates received an aggregate annual management fee in an amount per year equal to $1.0 million. On December 5, 2012, the agreement was amended to lower the per year management fee to $0.8 million beginning January 1, 2013. The agreement was terminated in the second quarter of 2015 with an effective date of September 24, 2014 to reflect Mr. Meister’s resignation as Chief Executive Officer. The Company incurred management fees of $0.2 million for the three months ended March 31, 2015. On November 12, 2012, the Compensation Committee of Group Holdings granted to Liberty Lane options to purchase shares of Common Stock equal to approximately 1.4% of the fully diluted equity of Group Holdings. The options vest if a liquidity event occurs such that the Investors achieve a certain return on their investment. These awards were cancelled in the second quarter of 2015 to reflect Mr. Meister’s resignation as Chief Executive Officer, and the Company issued 38,054 Multiple of Money (“MoM”) Option Awards to Mr. Meister during 2015. Commercial Transactions There were three entities for the three months ended March 31, 2016 and four entities for the three months ended March 31, 2015 in which THL or its affiliates held a 10% or greater interest that provided services exceeding $120,000 in value to the Company. The services included facilities management, audio conferencing and information technology services. The aggregate fees for these services were $0.4 million and $1.6 million for the three months ended March 31, 2016 and 2015, respectively. One of the Company’s directors, Blane Walter, acquired a 10% or greater interest in and became a director of an entity in 2013 which provided relationship enterprise technology solutions to the Company exceeding $120,000 in value over the previous twelve month period. No services were provided for the three months ended March 31, 2016 and services for fees of $1.8 million were provided for the three months ended March 31, 2015. Debt Instruments In 2014, affiliates of Thomas H. Lee Partners, L.P., Liberty Lane and Blane Walter purchased $25.0 million of Junior Lien Secured Notes and $26.3 million of the Company’s 10% Senior Unsecured Notes due 2018 for a total consideration of $50.0 million as described in Note 6.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	13. Fair Value Measurements The Company’s financial instruments include cash and cash equivalents, accounts receivables, unbilled services, accounts payable, short-term borrowings, capital leases and other financing arrangements as well as deferred revenues and client advances. Due to the short-term nature of such instruments, the Company believes their carrying values approximate fair value. Please refer to Note 6 for discussion of the Company’s debt instruments. The Company’s contingent consideration obligations are carried at fair value considering the Company’s best estimates as to the probable timing and amount of settlement (level 3 within the fair value hierarchy). As of March 31, 2016, the contingent consideration obligations had an aggregate fair value of $0.4 million, which is included in accrued expenses in the consolidated balance sheets. The Company’s deferred compensation plan provides eligible management and other highly compensated employees with the opportunity to defer their compensation and to receive the deferred amounts in the future or upon termination of employment with the Company. The Company invests in the underlying mutual fund investments available to plan participants through investments held in a rabbi trust, which generally offset the liability associated with the deferred compensation plan. These securities are classified as trading securities and carried at fair value (level 1 within the fair value hierarchy) of $10.6 million and $10.8 million as of March 31, 2016 and December 31, 2015 and included in other assets in the consolidated balance sheets. Gains and losses are included in SG&A expenses.

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Segment Information	14. Segment Information The Company provides services through two reportable segments, Clinical and Commercial. Each reportable business segment is comprised of multiple service offerings that, when combined, create a fully integrated biopharmaceutical outsourced services provider. Clinical provides a continuum of services spanning phases I-IV of clinical development. Commercial, provides commercialization, medication adherence and consulting services to biopharmaceutical companies. The Clinical and Commercial segments provide services to the other segments primarily in connection with the delivery of services to the end client. The Company accounts for intersegment sales on prices that management considers to be consistent with market pricing. Total intersegments sales from Clinical to Commercial was $0.1 million and $0.6 million for the three months ended March 31, 2016 and 2015, respectively. Total intersegment sales from Commercial to Clinical or Corporate and other was $4.4 million and $2.6 million for the three months ended March 31, 2016 and 2015, respectively. Management measures and evaluates the Company’s operating segments based on segment net revenues and adjusted operating income. The results of these reportable business segments are regularly reviewed by the Company’s chief operating decision maker, the Chief Executive Officer. Certain costs are excluded from segment operating income because management evaluates the operating results of the segments excluding such charges. These items include depreciation and amortization; certain foreign currency impacts; net charges associated with acquisitions; certain legal charges, net of insurance recoveries; certain asset impairment charges; stock-based compensation; as well as corporate and other unallocated expenses. The Corporate and other unallocated expenses primarily consist of expenses for corporate overhead functions such as finance, human resources, information technology, facilities and legal; restructuring and related charges; and certain expenses incurred in connection with the management agreements with affiliates of certain shareholders of the Parent. Although these amounts are excluded from segment operating income, as applicable, they are included in reported consolidated operating loss and in the reconciliations presented below. The Company has not presented segment assets since management does not evaluate the Company’s operating segments using this information. The Company has an agreement to provide commercialization services to a biopharmaceutical client for launch of certain products in return for a royalty on the client’s net revenues. The results of this arrangement are included in Corporate and other as the contract is managed and evaluated on a corporate level. As these activities were included in the Commercial segment prior to the three months ended September 30, 2015, segment information for the three months ended March 31, 2015 has been restated to include these results in Corporate and other and Commercial recognized intersegment revenues related to performing services under this arrangement. Selected information for each reportable segment is as follows (in thousands): For the Three Months Ended March 31, 2016 2015 Net Revenues Clinical $ 254,859 $ 219,664 Commercial 290,926 234,546 Intersegment revenues (4,489 ) (3,233 ) Consolidated net revenues $ 541,296 $ 450,977 Adjusted Segment Operating Income (Loss) Clinical $ 42,736 $ 25,649 Commercial 48,920 31,879 Corporate and other (12,324 ) (8,898 ) Reportable segments adjusted operating income (loss) 79,332 48,630 Depreciation and amortization (23,763 ) (25,003 ) Stock-based compensation (1,417 ) (470 ) Other unallocated charges (8,988 ) (5,599 ) Operating income (loss) 45,164 17,558 Interest income (expense), net (55,853 ) (56,463 ) Gain on extinguishment of debt 221 — Income (loss) before income tax (provision) benefit and income (loss) from equity investments $ (10,468 ) $ (38,905 )

Guarantor Financial Information

Guarantor Financial Information	3 Months Ended
	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Guarantor Financial Information	15. Guarantor Financial Information Borrowings under each of our Senior Secured Credit Facilities, ABL Facility, Senior Secured Notes, Junior Lien Secured Notes and Senior Unsecured Notes are guaranteed by certain of the Company’s domestic wholly-owned subsidiaries (the “Guarantor Subsidiaries”). The guarantees are full and unconditional and joint and several. The Company’s Senior Secured Credit Facility, ABL Facility, Senior Secured Notes, Junior Lien Secured Notes and Senior Unsecured Notes are not guaranteed by certain of the Company’s subsidiaries, including all of its non-U.S. subsidiaries or non-wholly owned subsidiaries. The following supplemental financial information sets forth, on a condensed consolidating basis, balance sheet information, results of operations, comprehensive loss and cash flow information for inVentiv Health, Inc., the Guarantor Subsidiaries and other subsidiaries (the “Non-Guarantor Subsidiaries”). The supplemental financial information reflects the investments of inVentiv Health, Inc.’s investment in the Guarantor Subsidiaries and Non-Guarantor Subsidiaries using the equity method of accounting. Subsequent to the issuance of the March 31, 2015 condensed consolidated financial statements, management determined that within the condensed consolidating statement of cash flows, certain intercompany transfers historically presented on a gross basis within operating, investing and financing activities represent centralized treasury activities that are more appropriately presented on a net basis within investing and financing activities between the respective parent, guarantor, and non guarantor entities. The aforementioned items have been corrected in the condensed consolidating statements of cash flows for the three months ended March 31, 2015. The corrections had no impact on the Company’s consolidated financial position, results of operations or cash flows. 15. Guarantor Financial Information (Continued) CONDENSED CONSOLIDATING BALANCE SHEET INFORMATION At March 31, 2016 (in thousands, except share and per share amounts) inVentiv Guarantor Non-Guarantor Health, Inc. Subsidiaries Subsidiaries Eliminations Total ASSETS Current assets: Cash and cash equivalents $ 27,758 — $ 136,644 $ (87,289 ) $ 77,113 Restricted cash 1,716 — 838 — 2,554 Accounts receivable, net of allowances for doubtful accounts — 266,930 61,396 — 328,326 Unbilled services — 223,422 38,301 — 261,723 Intercompany receivables 504,621 825,469 84,860 (1,414,950 ) — Prepaid expenses and other current assets 7,364 19,001 18,694 — 45,059 Income tax receivable 26 — 996 — 1,022 Total current assets 541,485 1,334,822 341,729 (1,502,239 ) 715,797 Property and equipment, net 21,369 98,916 18,887 — 139,172 Goodwill — 855,317 41,448 — 896,765 Intangible assets, net — 319,311 6,608 — 325,919 Non-current deferred tax assets — — 10,421 — 10,421 Other assets 20,331 4,330 15,060 — 39,721 Non-current intercompany receivables 429,168 28,867 — (458,035 ) — Investment in consolidated subsidiaries 700,686 107,127 — (807,813 ) — Total assets $ 1,713,039 $ 2,748,690 $ 434,153 $ (2,768,087 ) $ 2,127,795 LIABILITIES AND STOCKHOLDER’S (DEFICIT) EQUITY Current liabilities: Current portion of capital lease obligations and other financing arrangements $ 1,429 $ 23,831 $ 79,265 $ (79,229 ) $ 25,296 Accrued payroll, accounts payable and accrued expenses 78,168 182,536 66,304 (8,060 ) 318,948 Intercompany payables 857,790 537,244 19,916 (1,414,950 ) — Income taxes payable — 449 3,380 — 3,829 Deferred revenue and client advances — 189,789 56,832 — 246,621 Total current liabilities 937,387 933,849 225,697 (1,502,239 ) 594,694 Capital lease obligations, net of current portion — 45,512 13 — 45,525 Long-term debt, net of current portion 1,547,653 569,479 — — 2,117,132 Non-current income tax liability — 4,807 2,760 — 7,567 Deferred tax liability 74 77,854 1,178 — 79,106 Other non-current liabilities 12,902 31,599 22,249 — 66,750 Non-current intercompany liabilities — 429,157 28,878 (458,035 ) — Total liabilities 2,498,016 2,092,257 280,775 (1,960,274 ) 2,910,774 Total inVentiv Health, Inc. stockholder’s deficit (784,977 ) 656,433 151,380 (807,813 ) (784,977 ) Noncontrolling interest — — 1,998 — 1,998 Total stockholder’s deficit (784,977 ) 656,433 153,378 (807,813 ) (782,979 ) Total liabilities and stockholder’s deficit $ 1,713,039 $ 2,748,690 $ 434,153 $ (2,768,087 ) $ 2,127,795 15. Guarantor Financial Information (Continued) CONDENSED CONSOLIDATING BALANCE SHEET INFORMATION At December 31, 2015 (in thousands, except share and per share amounts) inVentiv Guarantor Non-Guarantor Health, Inc. Subsidiaries Subsidiaries Eliminations Total ASSETS Current assets: Cash and cash equivalents $ 55,226 — $ 148,970 $ (82,879 ) $ 121,317 Restricted cash 226 — 1,381 — 1,607 Accounts receivable, net of allowances for doubtful accounts — 292,548 66,533 — 359,081 Unbilled services — 174,070 33,395 — 207,465 Intercompany receivables 529,457 840,499 18,211 (1,388,167 ) — Prepaid expenses and other current assets 8,839 11,401 22,690 — 42,930 Income tax receivable 104 — 1,076 (104 ) 1,076 Total current assets 593,852 1,318,518 292,256 (1,471,150 ) 733,476 Property and equipment, net 23,227 101,507 17,298 — 142,032 Goodwill — 855,317 40,052 — 895,369 Intangible assets, net — 328,239 6,407 — 334,646 Non-current deferred tax assets — — 10,032 — 10,032 Other assets 19,084 4,491 13,559 — 37,134 Non-current intercompany receivables 416,161 29,235 35,021 (480,417 ) — Investment in consolidated subsidiaries 676,479 93,191 — (769,670 ) — Total assets $ 1,728,803 $ 2,730,498 $ 414,625 $ (2,721,237 ) $ 2,152,689 LIABILITIES AND STOCKHOLDER’S (DEFICIT) EQUITY Current liabilities: Current portion of capital lease obligations and other financing arrangements $ 1,936 $ 21,324 $ 73,355 $ (73,282 ) $ 23,333 Accrued payroll, accounts payable and accrued expenses 71,953 200,063 71,307 (9,597 ) 333,726 Intercompany payables 820,965 542,500 24,702 (1,388,167 ) — Income taxes payable — 165 5,423 (104 ) 5,484 Deferred revenue and client advances — 190,828 55,828 — 246,656 Total current liabilities 894,854 954,880 230,615 (1,471,150 ) 609,199 Capital lease obligations, net of current portion — 45,247 11 — 45,258 Long-term debt, net of current portion 1,533,197 568,688 — — 2,101,885 Non-current income tax liability — 4,806 1,136 — 5,942 Deferred tax liability 74 73,047 239 — 73,360 Other non-current liabilities 38,494 30,896 18,763 — 88,153 Non-current intercompany liabilities 34,920 416,260 29,237 (480,417 ) — Total liabilities 2,501,539 2,093,824 280,001 (1,951,567 ) 2,923,797 Total inVentiv Health, Inc. stockholder’s deficit (772,736 ) 636,674 132,996 (769,670 ) (772,736 ) Noncontrolling interest — — 1,628 — 1,628 Total stockholder’s deficit (772,736 ) 636,674 134,624 (769,670 ) (771,108 ) Total liabilities and stockholder’s deficit $ 1,728,803 $ 2,730,498 $ 414,625 $ (2,721,237 ) $ 2,152,689 15. Guarantor Financial Information (Continued) CONSOLIDATING STATEMENT OF OPERATIONS Three Months Ended March 31, 2016 (in thousands) inVentiv Guarantor Non-Guarantor Health, Inc. Subsidiaries Subsidiaries Eliminations Total Net revenues $ — $ 419,336 $ 129,933 $ (7,973 ) $ 541,296 Reimbursed out-of-pocket expenses — 83,818 7,214 (49 ) 90,983 Total revenues — 503,154 137,147 (8,022 ) 632,279 Operating expenses: Cost of revenues — 300,392 79,298 (7,314 ) 372,376 Reimbursable out-of-pocket expenses — 83,818 7,214 (49 ) 90,983 Selling, general and administrative expenses 21,129 71,369 31,917 (659 ) 123,756 Allocation of intercompany costs (13,899 ) 10,915 2,984 — — Total operating expenses 7,230 466,494 121,413 (8,022 ) 587,115 Operating income (loss) (7,230 ) 36,660 15,734 — 45,164 Gain on extinguishment of debt 221 — — — 221 Interest income (expense), net (43,831 ) (12,277 ) 255 — (55,853 ) Intercompany interest income (expense) 12,975 (12,715 ) (260 ) — — Income (loss) before income tax (provision) benefit and income (loss) from equity investments (37,865 ) 11,668 15,729 — (10,468 ) Income tax (provision) benefit — (5,145 ) (3,031 ) — (8,176 ) Income (loss) before income (loss) from equity investments (37,865 ) 6,523 12,698 — (18,644 ) Income (loss) from equity investments 18,788 10,574 — (29,357 ) 5 Net income (loss) (19,077 ) 17,097 12,698 (29,357 ) (18,639 ) Less: Net (income) loss attributable to the noncontrolling interest — — (438 ) — (438 ) Net income (loss) attributable to inVentiv Health, Inc. $ (19,077 ) $ 17,097 $ 12,260 $ (29,357 ) $ (19,077 ) 15. Guarantor Financial Information (Continued) CONSOLIDATING STATEMENT OF OPERATIONS Three Months Ended March 31, 2015 (in thousands) inVentiv Guarantor Non-Guarantor Health, Inc. Subsidiaries Subsidiaries Eliminations Total Net revenues $ — $ 346,981 $ 109,751 $ (5,755 ) $ 450,977 Reimbursed out-of-pocket expenses — 59,616 7,783 (76 ) 67,323 Total revenues — 406,597 117,534 (5,831 ) 518,300 Operating expenses: Cost of revenues — 236,463 69,304 (5,262 ) 300,505 Reimbursable out-of-pocket expenses — 59,616 7,783 (76 ) 67,323 Selling, general and administrative expenses 16,087 84,539 32,781 (493 ) 132,914 Allocation of intercompany costs (9,900 ) 7,944 1,956 — — Total operating expenses 6,187 388,562 111,824 (5,831 ) 500,742 Operating income (loss) (6,187 ) 18,035 5,710 — 17,558 Interest income (expense), net (44,398 ) (12,169 ) 104 — (56,463 ) Intercompany interest income (expense) 11,122 (10,972 ) (150 ) — — Income (loss) before income tax (provision) benefit and income (loss) from equity investments (39,463 ) (5,106 ) 5,664 — (38,905 ) Income tax (provision) benefit — (2,975 ) (1,553 ) — (4,528 ) Income (loss) before income (loss) from equity investments (39,463 ) (8,081 ) 4,111 — (43,433 ) Income (loss) from equity investments (5,622 ) 1,630 — 2,463 (1,529 ) Net income (loss) (45,085 ) (6,451 ) 4,111 2,463 (44,962 ) Less: Net (income) loss attributable to the noncontrolling interest — — (123 ) — (123 ) Net income (loss) attributable to inVentiv Health, Inc. $ (45,085 ) $ (6,451 ) $ 3,988 $ 2,463 $ (45,085 ) 15. Guarantor Financial Information (Continued) CONSOLIDATING STATEMENT OF COMPREHENSIVE LOSS Three Months Ended March 31, 2016 (in thousands) inVentiv Guarantor Non-Guarantor Health, Inc. Subsidiaries Subsidiaries Eliminations Total Net Income (loss) $ (19,077 ) $ 17,097 $ 12,698 $ (29,357 ) $ (18,639 ) Other comprehensive income (loss): Foreign currency translation adjustment 5,419 2,662 6,119 (8,781 ) 5,419 Total other comprehensive income (loss) 5,419 2,662 6,119 (8,781 ) 5,419 Total comprehensive income (loss) (13,658 ) 19,759 18,817 (38,138 ) (13,220 ) Less: Comprehensive (income) loss attributable to the noncontrolling interest — — (438 ) — (438 ) Total comprehensive income (loss) attributable to inVentiv Health, Inc. $ (13,658 ) $ 19,759 $ 18,379 $ (38,138 ) $ (13,658 ) 15. Guarantor Financial Information (Continued) CONSOLIDATING STATEMENT OF COMPREHENSIVE LOSS Three Months Ended March 31, 2015 (in thousands) inVentiv Guarantor Non-Guarantor Health, Inc. Subsidiaries Subsidiaries Eliminations Total Net Income (loss) $ (45,085 ) $ (6,451 ) $ 4,111 $ 2,463 $ (44,962 ) Other comprehensive income (loss): Foreign currency translation adjustment (5,445 ) (5,435 ) (4,011 ) 9,446 (5,445 ) Total other comprehensive income (loss) (5,445 ) (5,435 ) (4,011 ) 9,446 (5,445 ) Total comprehensive income (loss) (50,530 ) (11,886 ) 100 11,909 (50,407 ) Less: Comprehensive (income) loss attributable to the noncontrolling interest — — (123 ) — (123 ) Total comprehensive income (loss) attributable to inVentiv Health, Inc. $ (50,530 ) $ (11,886 ) $ (23 ) $ 11,909 $ (50,530 ) 15. Guarantor Financial Information (Continued) CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS Three Months Ended March 31, 2016 (in thousands) inVentiv Guarantor Non-Guarantor Health, Inc. Subsidiaries Subsidiaries Eliminations Total Cash flows from operating activities: Net cash provided by (used in) operating activities $ (36,631 ) $ 15,585 $ 19,486 $ (8,060 ) $ (9,620 ) Cash flows from investing activities: Purchases of property and equipment (1,811 ) (1,401 ) (2,958 ) — (6,170 ) Proceeds from vehicle sales and rebates on vehicle leases — 3,979 — — 3,979 Intercompany transfers 37,937 17,988 — (55,925 ) — Other, net (1,491 ) — 525 — (966 ) Net cash provided by (used in) investing activities 34,635 20,566 (2,433 ) (55,925 ) (3,157 ) Cash flows from financing activities: Repayments on capital leases and other financing arrangements (972 ) (7,896 ) (39 ) — (8,907 ) Repurchase of Notes (22,790 ) — — — (22,790 ) Payment on installment note and contingent consideration related to acquisition (2,174 ) — — — (2,174 ) Intercompany transfers — (28,255 ) (31,320 ) 59,575 — Other, net 464 — (68 ) — 396 Net cash provided by (used in) financing activities (25,472 ) (36,151 ) (31,427 ) 59,575 (33,475 ) Effects of foreign currency exchange rate changes on cash — — 2,048 — 2,048 Net increase (decrease) in cash and cash equivalents (27,468 ) — (12,326 ) (4,410 ) (44,204 ) Cash and cash equivalents, beginning of period 55,226 — 148,970 (82,879 ) 121,317 Cash and cash equivalents, end of period $ 27,758 $ — $ 136,644 $ (87,289 ) $ 77,113 15. Guarantor Financial Information (Continued) CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS Three Months Ended March 31, 2015 (in thousands) inVentiv Guarantor Non-Guarantor Health, Inc. Subsidiaries Subsidiaries Eliminations Total Cash flows from operating activities: Net cash provided by (used in) operating activities $ (37,855 ) $ 37,407 $ 8,984 $ (6,385 ) $ 2,151 Cash flows from investing activities: Purchases of property and equipment (2,777 ) (5,199 ) (1,823 ) — (9,799 ) Proceeds from vehicle sales and rebates on vehicle leases — 3,093 — — 3,093 Intercompany transfers 51,656 — — (51,656 ) — Other, net (238 ) — — — (238 ) Net cash provided by (used in) investing activities 48,641 (2,106 ) (1,823 ) (51,656 ) (6,944 ) Cash flows from financing activities: Repayments on capital leases and other financing arrangements (983 ) (7,816 ) (125 ) — (8,924 ) Borrowings under line of credit 17,000 — — — 17,000 Repayments on line of credit (17,000 ) — — — (17,000 ) Payment on installment note and contingent consideration related to acquisition (1,917 ) — — — (1,917 ) Intercompany transfers — (30,924 ) 6,980 23,944 — Other, net 93 — (68 ) — 25 Net cash provided by (used in) financing activities (2,807 ) (38,740 ) 6,787 23,944 (10,816 ) Effects of foreign currency exchange rate changes on cash — — (2,797 ) — (2,797 ) Net increase (decrease) in cash and cash equivalents 7,979 (3,439 ) 11,151 (34,097 ) (18,406 ) Cash and cash equivalents, beginning of period 19,643 3,439 86,014 (52,037 ) 57,059 Cash and cash equivalents, end of period $ 27,622 $ — $ 97,165 $ (86,134 ) $ 38,653

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Reclassifications	Reclassifications In the Company’s 2015 financial statements, the Company reclassified certain costs from selling, general and administrative (“SG&A”) expenses to cost of revenues to conform to the presentation adopted for 2015. The revised classification aligns all personnel and related costs associated with service delivery within cost of revenues, along with the associated information technology costs supporting these processes. These changes better harmonize the accounting policies of the group, and are consistent with how management is assessing performance and managing costs. As a result of the revision in the classification of the costs, the previously reported SG&A was reduced by $9.3 million for the three months ended March 31, 2015, and cost of revenues has increased by a corresponding amount. The reclassification had no impact on our consolidated financial position, net operating results included in our statements of operations or cash flows.

Goodwill (Tables)

Goodwill (Tables)	3 Months Ended
	Mar. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Carrying Amount of Goodwill	The following table sets forth the carrying amount of goodwill for each segment as of March 31, 2016 and December 31, 2015 (in thousands): Clinical Commercial Total Net goodwill at December 31, 2015 $ 382,215 $ 513,154 $ 895,369 Foreign currency translation (1 ) 1,397 1,396 Net goodwill at March 31, 2016 $ 382,214 $ 514,551 $ 896,765

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Carrying Amount of Intangible Assets	The following table sets forth the carrying amount of the Company’s intangible assets as of March 31, 2016 and December 31, 2015 (in thousands): March 31, 2016 December 31, 2015 Accumulated Accumulated Gross Amortization Net Gross Amortization Net Customer relationships $ 366,169 $ (156,458 ) $ 209,711 $ 365,777 $ (148,679 ) $ 217,098 Technology 27,090 (26,364 ) 726 27,003 (26,206 ) 797 Tradenames subject to amortization 18,314 (16,787 ) 1,527 18,293 (16,657 ) 1,636 Backlog 95,029 (90,783 ) 4,246 95,014 (89,427 ) 5,587 Other 1,020 (615 ) 405 1,020 (585 ) 435 Total finite-lived intangible assets 507,622 (291,007 ) 216,615 507,107 (281,554 ) 225,553 Tradenames not subject to amortization 109,304 — 109,304 109,093 — 109,093 Total intangible assets $ 616,926 $ (291,007 ) $ 325,919 $ 616,200 $ (281,554 ) $ 334,646

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Summary of Debt	The Company’s indebtedness is summarized as follows (in thousands): March 31, December 31, 2016 2015 Senior Secured Credit Facilities: Term Loan Facility B3 loans, due 2018 $ 129,645 $ 129,645 Term Loan Facility B4 loans, due 2018 445,694 445,694 Senior Secured Notes, due 2018 625,000 625,000 ABL Facility — — Junior Lien Secured Notes, due 2018 579,837 569,691 Senior Unsecured Notes, due 2018 376,316 376,316 International Facility — — Capital leases and other financing arrangements 70,821 68,591 Total borrowings 2,227,313 2,214,937 Less: unamortized premium (discount) (7,993 ) (9,030 ) Less: unamortized deferred financing costs (31,367 ) (35,431 ) Less: current portion of capital leases and other financing arrangements (25,296 ) (23,333 ) Total long-term borrowings, net of current portion $ 2,162,657 $ 2,147,143
Summary of Carrying Amounts and Estimated Fair Values of Long-Term Debt	The carrying amounts and the estimated fair values of long-term debt as of March 31, 2016 and December 31, 2015 are as follows (in thousands): March 31, 2016 December 31, 2015 Carrying value Estimated fair value Carrying value Estimated fair value Term Loan Facility $ 568,497 $ 573,576 $ 567,673 $ 570,051 Senior Secured Notes 619,410 643,750 618,616 633,594 Junior Lien Secured Notes 564,027 583,461 551,552 537,646 Senior Unsecured Notes 365,197 372,553 364,043 371,142

Termination Benefits and Othe27

Termination Benefits and Other Cost Reduction Actions (Tables)	3 Months Ended
	Mar. 31, 2016
Restructuring And Related Activities [Abstract]
Summary of Company's Restructuring Costs	Expenses related to these actions that include real estate consolidations, elimination of redundant functions and employees, are summarized below (in thousands): For the Three Months Ended March 31, 2016 2015 Employee severance and related costs $ 2,745 $ 2,579 Facilities-related costs 1,385 176 Total $ 4,130 $ 2,755
Summary of Company's Restructuring Reserve	The following table summarizes the Company’s restructuring reserve as of March 31, 2016 and December 31, 2015 (in thousands): Balance at Balance at December March 31, 2015 Net Costs Cash Payments 2016 Employee severance and related costs $ 4,245 $ 2,745 $ (3,115 ) $ 3,875 Facilities-related costs 3,942 1,385 (1,388 ) 3,939 Total $ 8,187 $ 4,130 $ (4,503 ) $ 7,814

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Schedule of Selected Information for Each Reportable Segment	Selected information for each reportable segment is as follows (in thousands): For the Three Months Ended March 31, 2016 2015 Net Revenues Clinical $ 254,859 $ 219,664 Commercial 290,926 234,546 Intersegment revenues (4,489 ) (3,233 ) Consolidated net revenues $ 541,296 $ 450,977 Adjusted Segment Operating Income (Loss) Clinical $ 42,736 $ 25,649 Commercial 48,920 31,879 Corporate and other (12,324 ) (8,898 ) Reportable segments adjusted operating income (loss) 79,332 48,630 Depreciation and amortization (23,763 ) (25,003 ) Stock-based compensation (1,417 ) (470 ) Other unallocated charges (8,988 ) (5,599 ) Operating income (loss) 45,164 17,558 Interest income (expense), net (55,853 ) (56,463 ) Gain on extinguishment of debt 221 — Income (loss) before income tax (provision) benefit and income (loss) from equity investments $ (10,468 ) $ (38,905 )

Guarantor Financial Informati29

Guarantor Financial Information (Tables)	3 Months Ended
	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Condensed Consolidating Balance Sheet Information	CONDENSED CONSOLIDATING BALANCE SHEET INFORMATION At March 31, 2016 (in thousands, except share and per share amounts) inVentiv Guarantor Non-Guarantor Health, Inc. Subsidiaries Subsidiaries Eliminations Total ASSETS Current assets: Cash and cash equivalents $ 27,758 — $ 136,644 $ (87,289 ) $ 77,113 Restricted cash 1,716 — 838 — 2,554 Accounts receivable, net of allowances for doubtful accounts — 266,930 61,396 — 328,326 Unbilled services — 223,422 38,301 — 261,723 Intercompany receivables 504,621 825,469 84,860 (1,414,950 ) — Prepaid expenses and other current assets 7,364 19,001 18,694 — 45,059 Income tax receivable 26 — 996 — 1,022 Total current assets 541,485 1,334,822 341,729 (1,502,239 ) 715,797 Property and equipment, net 21,369 98,916 18,887 — 139,172 Goodwill — 855,317 41,448 — 896,765 Intangible assets, net — 319,311 6,608 — 325,919 Non-current deferred tax assets — — 10,421 — 10,421 Other assets 20,331 4,330 15,060 — 39,721 Non-current intercompany receivables 429,168 28,867 — (458,035 ) — Investment in consolidated subsidiaries 700,686 107,127 — (807,813 ) — Total assets $ 1,713,039 $ 2,748,690 $ 434,153 $ (2,768,087 ) $ 2,127,795 LIABILITIES AND STOCKHOLDER’S (DEFICIT) EQUITY Current liabilities: Current portion of capital lease obligations and other financing arrangements $ 1,429 $ 23,831 $ 79,265 $ (79,229 ) $ 25,296 Accrued payroll, accounts payable and accrued expenses 78,168 182,536 66,304 (8,060 ) 318,948 Intercompany payables 857,790 537,244 19,916 (1,414,950 ) — Income taxes payable — 449 3,380 — 3,829 Deferred revenue and client advances — 189,789 56,832 — 246,621 Total current liabilities 937,387 933,849 225,697 (1,502,239 ) 594,694 Capital lease obligations, net of current portion — 45,512 13 — 45,525 Long-term debt, net of current portion 1,547,653 569,479 — — 2,117,132 Non-current income tax liability — 4,807 2,760 — 7,567 Deferred tax liability 74 77,854 1,178 — 79,106 Other non-current liabilities 12,902 31,599 22,249 — 66,750 Non-current intercompany liabilities — 429,157 28,878 (458,035 ) — Total liabilities 2,498,016 2,092,257 280,775 (1,960,274 ) 2,910,774 Total inVentiv Health, Inc. stockholder’s deficit (784,977 ) 656,433 151,380 (807,813 ) (784,977 ) Noncontrolling interest — — 1,998 — 1,998 Total stockholder’s deficit (784,977 ) 656,433 153,378 (807,813 ) (782,979 ) Total liabilities and stockholder’s deficit $ 1,713,039 $ 2,748,690 $ 434,153 $ (2,768,087 ) $ 2,127,795 CONDENSED CONSOLIDATING BALANCE SHEET INFORMATION At December 31, 2015 (in thousands, except share and per share amounts) inVentiv Guarantor Non-Guarantor Health, Inc. Subsidiaries Subsidiaries Eliminations Total ASSETS Current assets: Cash and cash equivalents $ 55,226 — $ 148,970 $ (82,879 ) $ 121,317 Restricted cash 226 — 1,381 — 1,607 Accounts receivable, net of allowances for doubtful accounts — 292,548 66,533 — 359,081 Unbilled services — 174,070 33,395 — 207,465 Intercompany receivables 529,457 840,499 18,211 (1,388,167 ) — Prepaid expenses and other current assets 8,839 11,401 22,690 — 42,930 Income tax receivable 104 — 1,076 (104 ) 1,076 Total current assets 593,852 1,318,518 292,256 (1,471,150 ) 733,476 Property and equipment, net 23,227 101,507 17,298 — 142,032 Goodwill — 855,317 40,052 — 895,369 Intangible assets, net — 328,239 6,407 — 334,646 Non-current deferred tax assets — — 10,032 — 10,032 Other assets 19,084 4,491 13,559 — 37,134 Non-current intercompany receivables 416,161 29,235 35,021 (480,417 ) — Investment in consolidated subsidiaries 676,479 93,191 — (769,670 ) — Total assets $ 1,728,803 $ 2,730,498 $ 414,625 $ (2,721,237 ) $ 2,152,689 LIABILITIES AND STOCKHOLDER’S (DEFICIT) EQUITY Current liabilities: Current portion of capital lease obligations and other financing arrangements $ 1,936 $ 21,324 $ 73,355 $ (73,282 ) $ 23,333 Accrued payroll, accounts payable and accrued expenses 71,953 200,063 71,307 (9,597 ) 333,726 Intercompany payables 820,965 542,500 24,702 (1,388,167 ) — Income taxes payable — 165 5,423 (104 ) 5,484 Deferred revenue and client advances — 190,828 55,828 — 246,656 Total current liabilities 894,854 954,880 230,615 (1,471,150 ) 609,199 Capital lease obligations, net of current portion — 45,247 11 — 45,258 Long-term debt, net of current portion 1,533,197 568,688 — — 2,101,885 Non-current income tax liability — 4,806 1,136 — 5,942 Deferred tax liability 74 73,047 239 — 73,360 Other non-current liabilities 38,494 30,896 18,763 — 88,153 Non-current intercompany liabilities 34,920 416,260 29,237 (480,417 ) — Total liabilities 2,501,539 2,093,824 280,001 (1,951,567 ) 2,923,797 Total inVentiv Health, Inc. stockholder’s deficit (772,736 ) 636,674 132,996 (769,670 ) (772,736 ) Noncontrolling interest — — 1,628 — 1,628 Total stockholder’s deficit (772,736 ) 636,674 134,624 (769,670 ) (771,108 ) Total liabilities and stockholder’s deficit $ 1,728,803 $ 2,730,498 $ 414,625 $ (2,721,237 ) $ 2,152,689
Consolidating Statement of Operations	CONSOLIDATING STATEMENT OF OPERATIONS Three Months Ended March 31, 2016 (in thousands) inVentiv Guarantor Non-Guarantor Health, Inc. Subsidiaries Subsidiaries Eliminations Total Net revenues $ — $ 419,336 $ 129,933 $ (7,973 ) $ 541,296 Reimbursed out-of-pocket expenses — 83,818 7,214 (49 ) 90,983 Total revenues — 503,154 137,147 (8,022 ) 632,279 Operating expenses: Cost of revenues — 300,392 79,298 (7,314 ) 372,376 Reimbursable out-of-pocket expenses — 83,818 7,214 (49 ) 90,983 Selling, general and administrative expenses 21,129 71,369 31,917 (659 ) 123,756 Allocation of intercompany costs (13,899 ) 10,915 2,984 — — Total operating expenses 7,230 466,494 121,413 (8,022 ) 587,115 Operating income (loss) (7,230 ) 36,660 15,734 — 45,164 Gain on extinguishment of debt 221 — — — 221 Interest income (expense), net (43,831 ) (12,277 ) 255 — (55,853 ) Intercompany interest income (expense) 12,975 (12,715 ) (260 ) — — Income (loss) before income tax (provision) benefit and income (loss) from equity investments (37,865 ) 11,668 15,729 — (10,468 ) Income tax (provision) benefit — (5,145 ) (3,031 ) — (8,176 ) Income (loss) before income (loss) from equity investments (37,865 ) 6,523 12,698 — (18,644 ) Income (loss) from equity investments 18,788 10,574 — (29,357 ) 5 Net income (loss) (19,077 ) 17,097 12,698 (29,357 ) (18,639 ) Less: Net (income) loss attributable to the noncontrolling interest — — (438 ) — (438 ) Net income (loss) attributable to inVentiv Health, Inc. $ (19,077 ) $ 17,097 $ 12,260 $ (29,357 ) $ (19,077 ) CONSOLIDATING STATEMENT OF OPERATIONS Three Months Ended March 31, 2015 (in thousands) inVentiv Guarantor Non-Guarantor Health, Inc. Subsidiaries Subsidiaries Eliminations Total Net revenues $ — $ 346,981 $ 109,751 $ (5,755 ) $ 450,977 Reimbursed out-of-pocket expenses — 59,616 7,783 (76 ) 67,323 Total revenues — 406,597 117,534 (5,831 ) 518,300 Operating expenses: Cost of revenues — 236,463 69,304 (5,262 ) 300,505 Reimbursable out-of-pocket expenses — 59,616 7,783 (76 ) 67,323 Selling, general and administrative expenses 16,087 84,539 32,781 (493 ) 132,914 Allocation of intercompany costs (9,900 ) 7,944 1,956 — — Total operating expenses 6,187 388,562 111,824 (5,831 ) 500,742 Operating income (loss) (6,187 ) 18,035 5,710 — 17,558 Interest income (expense), net (44,398 ) (12,169 ) 104 — (56,463 ) Intercompany interest income (expense) 11,122 (10,972 ) (150 ) — — Income (loss) before income tax (provision) benefit and income (loss) from equity investments (39,463 ) (5,106 ) 5,664 — (38,905 ) Income tax (provision) benefit — (2,975 ) (1,553 ) — (4,528 ) Income (loss) before income (loss) from equity investments (39,463 ) (8,081 ) 4,111 — (43,433 ) Income (loss) from equity investments (5,622 ) 1,630 — 2,463 (1,529 ) Net income (loss) (45,085 ) (6,451 ) 4,111 2,463 (44,962 ) Less: Net (income) loss attributable to the noncontrolling interest — — (123 ) — (123 ) Net income (loss) attributable to inVentiv Health, Inc. $ (45,085 ) $ (6,451 ) $ 3,988 $ 2,463 $ (45,085 )
Consolidating Statement of Comprehensive Loss	CONSOLIDATING STATEMENT OF COMPREHENSIVE LOSS Three Months Ended March 31, 2016 (in thousands) inVentiv Guarantor Non-Guarantor Health, Inc. Subsidiaries Subsidiaries Eliminations Total Net Income (loss) $ (19,077 ) $ 17,097 $ 12,698 $ (29,357 ) $ (18,639 ) Other comprehensive income (loss): Foreign currency translation adjustment 5,419 2,662 6,119 (8,781 ) 5,419 Total other comprehensive income (loss) 5,419 2,662 6,119 (8,781 ) 5,419 Total comprehensive income (loss) (13,658 ) 19,759 18,817 (38,138 ) (13,220 ) Less: Comprehensive (income) loss attributable to the noncontrolling interest — — (438 ) — (438 ) Total comprehensive income (loss) attributable to inVentiv Health, Inc. $ (13,658 ) $ 19,759 $ 18,379 $ (38,138 ) $ (13,658 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE LOSS Three Months Ended March 31, 2015 (in thousands) inVentiv Guarantor Non-Guarantor Health, Inc. Subsidiaries Subsidiaries Eliminations Total Net Income (loss) $ (45,085 ) $ (6,451 ) $ 4,111 $ 2,463 $ (44,962 ) Other comprehensive income (loss): Foreign currency translation adjustment (5,445 ) (5,435 ) (4,011 ) 9,446 (5,445 ) Total other comprehensive income (loss) (5,445 ) (5,435 ) (4,011 ) 9,446 (5,445 ) Total comprehensive income (loss) (50,530 ) (11,886 ) 100 11,909 (50,407 ) Less: Comprehensive (income) loss attributable to the noncontrolling interest — — (123 ) — (123 ) Total comprehensive income (loss) attributable to inVentiv Health, Inc. $ (50,530 ) $ (11,886 ) $ (23 ) $ 11,909 $ (50,530 )
Condensed Consolidating Statement of Cash Flows	CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS Three Months Ended March 31, 2016 (in thousands) inVentiv Guarantor Non-Guarantor Health, Inc. Subsidiaries Subsidiaries Eliminations Total Cash flows from operating activities: Net cash provided by (used in) operating activities $ (36,631 ) $ 15,585 $ 19,486 $ (8,060 ) $ (9,620 ) Cash flows from investing activities: Purchases of property and equipment (1,811 ) (1,401 ) (2,958 ) — (6,170 ) Proceeds from vehicle sales and rebates on vehicle leases — 3,979 — — 3,979 Intercompany transfers 37,937 17,988 — (55,925 ) — Other, net (1,491 ) — 525 — (966 ) Net cash provided by (used in) investing activities 34,635 20,566 (2,433 ) (55,925 ) (3,157 ) Cash flows from financing activities: Repayments on capital leases and other financing arrangements (972 ) (7,896 ) (39 ) — (8,907 ) Repurchase of Notes (22,790 ) — — — (22,790 ) Payment on installment note and contingent consideration related to acquisition (2,174 ) — — — (2,174 ) Intercompany transfers — (28,255 ) (31,320 ) 59,575 — Other, net 464 — (68 ) — 396 Net cash provided by (used in) financing activities (25,472 ) (36,151 ) (31,427 ) 59,575 (33,475 ) Effects of foreign currency exchange rate changes on cash — — 2,048 — 2,048 Net increase (decrease) in cash and cash equivalents (27,468 ) — (12,326 ) (4,410 ) (44,204 ) Cash and cash equivalents, beginning of period 55,226 — 148,970 (82,879 ) 121,317 Cash and cash equivalents, end of period $ 27,758 $ — $ 136,644 $ (87,289 ) $ 77,113 CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS Three Months Ended March 31, 2015 (in thousands) inVentiv Guarantor Non-Guarantor Health, Inc. Subsidiaries Subsidiaries Eliminations Total Cash flows from operating activities: Net cash provided by (used in) operating activities $ (37,855 ) $ 37,407 $ 8,984 $ (6,385 ) $ 2,151 Cash flows from investing activities: Purchases of property and equipment (2,777 ) (5,199 ) (1,823 ) — (9,799 ) Proceeds from vehicle sales and rebates on vehicle leases — 3,093 — — 3,093 Intercompany transfers 51,656 — — (51,656 ) — Other, net (238 ) — — — (238 ) Net cash provided by (used in) investing activities 48,641 (2,106 ) (1,823 ) (51,656 ) (6,944 ) Cash flows from financing activities: Repayments on capital leases and other financing arrangements (983 ) (7,816 ) (125 ) — (8,924 ) Borrowings under line of credit 17,000 — — — 17,000 Repayments on line of credit (17,000 ) — — — (17,000 ) Payment on installment note and contingent consideration related to acquisition (1,917 ) — — — (1,917 ) Intercompany transfers — (30,924 ) 6,980 23,944 — Other, net 93 — (68 ) — 25 Net cash provided by (used in) financing activities (2,807 ) (38,740 ) 6,787 23,944 (10,816 ) Effects of foreign currency exchange rate changes on cash — — (2,797 ) — (2,797 ) Net increase (decrease) in cash and cash equivalents 7,979 (3,439 ) 11,151 (34,097 ) (18,406 ) Cash and cash equivalents, beginning of period 19,643 3,439 86,014 (52,037 ) 57,059 Cash and cash equivalents, end of period $ 27,622 $ — $ 97,165 $ (86,134 ) $ 38,653

Organization and Business - Add

Organization and Business - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of reportable segments	2

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Line items]
Recognized loss on dissolution of a joint venture	$ (1.6)
SG&A Expenses [Member]
Organization, Consolidation and Presentation of Financial Statements [Line items]
Prior period reclassification adjustment	(9.3)
Cost of Revenues [Member]
Organization, Consolidation and Presentation of Financial Statements [Line items]
Prior period reclassification adjustment	$ 9.3
InVentiv Health, Inc. [Member]
Organization, Consolidation and Presentation of Financial Statements [Line items]
Minority interest owned percentage		60.00%

Goodwill - Schedule of Carrying

Goodwill - Schedule of Carrying Amount of Goodwill (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Goodwill [Line Items]
Net goodwill, Beginning balance	$ 895,369
Foreign currency translation	1,396
Net goodwill, Ending balance	896,765
Clinical [Member]
Goodwill [Line Items]
Net goodwill, Beginning balance	382,215
Foreign currency translation	(1)
Net goodwill, Ending balance	382,214
Commercial [Member]
Goodwill [Line Items]
Net goodwill, Beginning balance	513,154
Foreign currency translation	1,397
Net goodwill, Ending balance	$ 514,551

Goodwill - Additional Informati

Goodwill - Additional Information (Detail) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Accumulated goodwill impairment losses	$ 478.3	$ 478.3

Intangible Assets - Schedule of

Intangible Assets - Schedule of Carrying Amount of Intangible Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	$ 507,622	$ 507,107
Finite-lived intangible assets, Accumulated Amortization	(291,007)	(281,554)
Finite-lived intangible assets, Net	216,615	225,553
Intangible assets, Gross	616,926	616,200
Intangible assets, net	325,919	334,646
Customer Relationships [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	366,169	365,777
Finite-lived intangible assets, Accumulated Amortization	(156,458)	(148,679)
Finite-lived intangible assets, Net	209,711	217,098
Technology [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	27,090	27,003
Finite-lived intangible assets, Accumulated Amortization	(26,364)	(26,206)
Finite-lived intangible assets, Net	726	797
Tradenames [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	18,314	18,293
Finite-lived intangible assets, Accumulated Amortization	(16,787)	(16,657)
Finite-lived intangible assets, Net	1,527	1,636
Indefinite-lived intangible assets	109,304	109,093
Backlog [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	95,029	95,014
Finite-lived intangible assets, Accumulated Amortization	(90,783)	(89,427)
Finite-lived intangible assets, Net	4,246	5,587
Other [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	1,020	1,020
Finite-lived intangible assets, Accumulated Amortization	(615)	(585)
Finite-lived intangible assets, Net	$ 405	$ 435

Debt - Summary of Debt (Detail)

Debt - Summary of Debt (Detail) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Total borrowings	$ 2,227,313,000	$ 2,214,937,000
Less: unamortized premium (discount)	(7,993,000)	(9,030,000)
Less: unamortized deferred financing costs	(31,367,000)	(35,431,000)
Less: current portion of capital leases and other financing arrangements	(25,296,000)	(23,333,000)
Total long-term borrowings, net of current portion	2,162,657,000	2,147,143,000
Senior Secured Credit Facilities [Member]
Debt Instrument [Line Items]
Total borrowings	575,300,000
Senior Secured Credit Facilities [Member] | Term Loan Facility B3 Loans, Due 2018 [Member]
Debt Instrument [Line Items]
Total borrowings	129,645,000	129,645,000
Senior Secured Credit Facilities [Member] | Term Loan Facility B4 Loans, Due 2018 [Member]
Debt Instrument [Line Items]
Total borrowings	445,694,000	445,694,000
Senior Secured Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Total borrowings	625,000,000	625,000,000
ABL Facility [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Total borrowings	0
Junior Lien Secured Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Total borrowings	579,837,000	569,691,000
Senior Unsecured Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Total borrowings	376,316,000	376,316,000
Capital Leases and Other Financing Arrangements [Member]
Debt Instrument [Line Items]
Total borrowings	$ 70,821,000	$ 68,591,000

Debt - Summary of Debt (Parenth

Debt - Summary of Debt (Parenthetical) (Detail)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Senior Secured Credit Facilities [Member] | Term Loan Facility B3 Loans, Due 2018 [Member]
Debt Instrument [Line Items]
Maturity year	2,018	2,018
Senior Secured Credit Facilities [Member] | Term Loan Facility B4 Loans, Due 2018 [Member]
Debt Instrument [Line Items]
Maturity year	2,018	2,018
Senior Secured Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Maturity year	2,018	2,018
Junior Lien Secured Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Maturity year	2,018	2,018
Senior Unsecured Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Maturity year	2,018	2,018

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	Aug. 15, 2014	Aug. 12, 2014	Mar. 31, 2016	Dec. 31, 2015	Jul. 01, 2015	Aug. 16, 2013
Debt Instrument [Line Items]
Total borrowings			$ 2,227,313,000	$ 2,214,937,000
Repurchased and cancelled aggregate principal amount			23,700,000
Cash paid for repurchase of debt			22,790,000
Gain on extinguishment of debt			221,000
Net cash position in cash pool			34,400,000
Gross cash position in cash pool			113,600,000
Cash pool borrowings			79,200,000
Open Market Purchases [Member]
Debt Instrument [Line Items]
Cash paid for repurchase of debt			$ 23,100,000
Junior Lien Notes Exchange Offer [Member]
Debt Instrument [Line Items]
Debt instrument, total consideration		$ 50,000,000
Debt instrument, discount percentage		5.00%
Increase in margin of the term loan			0.25%
Senior Secured Credit Facilities [Member]
Debt Instrument [Line Items]
Total borrowings			$ 575,300,000
Senior Secured Credit Facilities [Member] | Term Loan Facility B3 Loans, Due 2018 [Member]
Debt Instrument [Line Items]
Total borrowings			$ 129,645,000	$ 129,645,000
Maturity year			2,018	2,018
Senior Secured Credit Facilities [Member] | Term Loan Facility B4 Loans, Due 2018 [Member]
Debt Instrument [Line Items]
Total borrowings			$ 445,694,000	$ 445,694,000
Maturity year			2,018	2,018
Senior Secured Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Total borrowings			$ 625,000,000	$ 625,000,000
Maturity year			2,018	2,018
ABL Facility [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Total borrowings			$ 0
Line of Credit Facility, Maximum Borrowing Capacity						$ 150,000,000
Debt Instrument, maturity date			Aug. 16, 2018
Line of Credit Facility, additional borrowing capacity			$ 131,200,000
ABL Facility [Member] | Letter of Credit [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			35,000,000
Amount outstanding			18,800,000
Junior Lien Secured Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Total borrowings			$ 579,837,000	$ 569,691,000
Maturity year			2,018	2,018
Junior Lien Secured Notes, Due 2018 [Member] | Junior Lien Notes Exchange Offer [Member]
Debt Instrument [Line Items]
Description of interest payment			six semi-annual interest payments
Debt instrument, cash interest rate	10.00%
Debt instrument, PIK interest rate	12.00%
Junior lien secured notes issued		$ 25,000,000
Issuance of Junior Lien Secured Notes for backstop fees	$ 7,000,000
Senior Unsecured Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Total borrowings			$ 376,316,000	$ 376,316,000
Maturity year			2,018	2,018
Senior Unsecured Notes, Due 2018 [Member] | Junior Lien Notes Exchange Offer [Member]
Debt Instrument [Line Items]
Exchange Offer Amount	$ 475,000,000
Debt instrument, interest rate of Junior Lien Secured Notes			10%/12%
Debt instrument, interest rate		10.00%
Maturity year	2,018	2,018
Debt instrument, total consideration		$ 26,300,000
Unamortized discount		$ 1,300,000
Capital Leases and Other Financing Arrangements [Member]
Debt Instrument [Line Items]
Total borrowings			$ 70,821,000	$ 68,591,000
International ABL Facility [Member]
Debt Instrument [Line Items]
Total borrowings			0
Line of Credit Facility, Maximum Borrowing Capacity			$ 14,900,000		$ 20,000,000

Debt - Summary of Carrying Amou

Debt - Summary of Carrying Amounts and Estimated Fair Values of Long-Term Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Senior Secured Credit Facilities [Member]
Debt Instrument [Line Items]
Carrying value	$ 568,497	$ 567,673
Estimated fair value	573,576	570,051
Senior Secured Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Carrying value	619,410	618,616
Estimated fair value	643,750	633,594
Junior Lien Secured Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Carrying value	564,027	551,552
Estimated fair value	583,461	537,646
Senior Unsecured Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Carrying value	365,197	364,043
Estimated fair value	$ 372,553	$ 371,142

Contingencies - Additional Info

Contingencies - Additional Information (Detail) - Master Services Agreement (MSA) [Member] - Pending Litigation [Member] - USD ($)	1 Months Ended		3 Months Ended
	Jan. 31, 2015	Dec. 31, 2013	Mar. 31, 2016
Cel-Sci Corporation Against PharmaNet [Member]
Loss Contingencies [Line Items]
Damages claim on arbitration description			October 31, 2013
Damages claim on arbitration			$ 50,000,000
inVentiv Health Clinical, LLC Against Cel-Sci Corporation [Member]
Loss Contingencies [Line Items]
Damages claim on arbitration	$ 2,000,000	$ 2,000,000
Counterclaim on other equitable remedies	$ 20,000,000

Concentration of Credit Risk -

Concentration of Credit Risk - Additional Information (Detail) - Customer Concentration Risk [Member] - Client	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Percentage of credit risk	12.00%
Number of clients accounted	1	0
Accounts Receivable [Member]
Concentration Risk [Line Items]
Percentage of credit risk	10.00%
Number of clients accounted	1
Maximum [Member] | Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Percentage of credit risk		10.00%

Common Stock and Stock Incent41

Common Stock and Stock Incentive Plans - Additional Information (Detail) - 2010 Equity Incentive Plan [Member] - USD ($)	Mar. 25, 2016	Jul. 02, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares approved for granted	106,218
2015 Exchange Program [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
New option award terms		one-for-one
Number of shares exchanged from RSU awards to Option awards		148,748
Incremental stock compensation cost for awards		$ 0
Option Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares approved for granted	102,496
Mom RSU and Time Based Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares approved for granted	3,722
Time Based Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of vesting under the plan		35.00%
Time Based Options [Member] | Option Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of vesting under the plan	35.00%
Performance Based Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of vesting under the plan		65.00%
Performance Based Options [Member] | Option Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of vesting under the plan	65.00%

Termination Benefits and Othe42

Termination Benefits and Other Cost Reduction Actions - Summary of Real Estate Consolidations, Elimination of Redundant Functions and Employees Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Restructuring And Related Activities [Abstract]
Employee severance and related costs	$ 2,745	$ 2,579
Facilities-related costs	1,385	176
Total	$ 4,130	$ 2,755

Termination Benefits and Othe43

Termination Benefits and Other Cost Reduction Actions - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Restructuring Cost And Reserve [Line Items]
Restructuring costs	$ 4,130	$ 2,755
Non cash portion of net costs related to abandoned assets	200
Clinical [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring costs	1,200	1,000
Commercial [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring costs	2,900	1,700
Corporate [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring costs		100
Cost of Revenues [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring costs	1,500	1,300
SG&A Expenses [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring costs	$ 2,600	$ 1,400

Termination Benefits and Othe44

Termination Benefits and Other Cost Reduction Actions - Summary of Company's Restructuring Reserve (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Restructuring Cost And Reserve [Line Items]
Restructuring Reserve, Beginning Balance	$ 8,187
Net Costs	4,130	$ 2,755
Cash Payments	(4,503)
Restructuring Reserve, Ending Balance	7,814
Employee Severance and Related Costs [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring Reserve, Beginning Balance	4,245
Net Costs	2,745
Cash Payments	(3,115)
Restructuring Reserve, Ending Balance	3,875
Facilities-Related Charges [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring Reserve, Beginning Balance	3,942
Net Costs	1,385
Cash Payments	(1,388)
Restructuring Reserve, Ending Balance	$ 3,939

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2016
Income Taxes [Line Items]
Consolidated effective tax rate	(78.10%)	(11.60%)
Scenario, Forecast [Member]
Income Taxes [Line Items]
Income tax expense related to amortization			$ 8.5
Estimated unamortized balance of tax deductible goodwill and indefinite-lived intangible assets			$ 111.4

Related Parties - Additional In

Related Parties - Additional Information (Detail)	Dec. 05, 2012USD ($)	Nov. 12, 2012	Aug. 31, 2010USD ($)	Mar. 31, 2016USD ($)Entity	Mar. 31, 2015USD ($)Entity	Dec. 31, 2015shares	Aug. 12, 2014USD ($)
Junior Lien Notes Exchange Offer [Member]
Related Party Transaction [Line Items]
Debt instrument, total consideration							$ 50,000,000
Junior Lien Secured Notes, Due 2018 [Member] | Junior Lien Notes Exchange Offer [Member]
Related Party Transaction [Line Items]
Junior lien secured notes issued							25,000,000
Senior Unsecured Notes, Due 2018 [Member] | Junior Lien Notes Exchange Offer [Member]
Related Party Transaction [Line Items]
Debt instrument, total consideration							$ 26,300,000
Senior unsecured notes interest percentage							10.00%
Mr. Meister [Member] | Multiple of Money ("MOM") Options [Member]
Related Party Transaction [Line Items]
Number of common stock shares issued for stock options and other stock awards | shares						38,054
Blane Walter [Member]
Related Party Transaction [Line Items]
Related party transaction service amount threshold				$ 120,000
Services fees				$ 0	$ 1,800,000
Blane Walter [Member] | InVentiv Health, Inc. [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Percentage of interest hold				10.00%
THL [Member]
Related Party Transaction [Line Items]
Management fee description				THL Management Agreement, THL Managers will receive an aggregate annual management fee in an amount per year equal to the greater of (a) $2.5 million or (b) 1.5% of EBITDA
Percentage of management fee in EBITDA			1.50%
Annual management fee			$ 2,500,000	$ 900,000	$ 700,000
Number of entities | Entity				3	4
Related parties, description of transaction				THL or its affiliates held a 10% or greater interest that provided services exceeding $120,000 in value to the Company
Related party transaction service amount threshold				$ 120,000
Services fees				$ 400,000	$ 1,600,000
THL [Member] | InVentiv Health, Inc. [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Percentage of interest hold						10.00%
Liberty Lane [Member]
Related Party Transaction [Line Items]
Annual management fee	$ 800,000		$ 1,000,000		$ 200,000
Percentage of common stock options granted as compensation		1.40%
Affiliates of Thomas H. Lee Partners L.P., Liberty Lane and Blane Walter [Member] | Junior Lien Notes Exchange Offer [Member]
Related Party Transaction [Line Items]
Debt instrument, total consideration							$ 50,000,000
Affiliates of Thomas H. Lee Partners L.P., Liberty Lane and Blane Walter [Member] | Junior Lien Secured Notes, Due 2018 [Member] | Junior Lien Notes Exchange Offer [Member]
Related Party Transaction [Line Items]
Junior lien secured notes issued							25,000,000
Affiliates of Thomas H. Lee Partners L.P., Liberty Lane and Blane Walter [Member] | Senior Unsecured Notes, Due 2018 [Member] | Junior Lien Notes Exchange Offer [Member]
Related Party Transaction [Line Items]
Debt instrument, total consideration							$ 26,300,000
Senior unsecured notes interest percentage							10.00%

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Fair Value, Inputs, Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Amount of contingent consideration obligation	$ 0.4
Fair Value, Inputs, Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Trading securities at fair value	$ 10.6	$ 10.8

Segment Information - Additiona

Segment Information - Additional Information (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)Segment	Mar. 31, 2015USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments | Segment	2
Intersegments sales	$ 541,296	$ 450,977
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Intersegments sales	(4,489)	(3,233)
Intersegment Eliminations [Member] | Clinical to Commercial [Member]
Segment Reporting Information [Line Items]
Intersegments sales	100	600
Intersegment Eliminations [Member] | Commercial To Clinical Or Corporate And Other Segment [Member]
Segment Reporting Information [Line Items]
Intersegments sales	$ 4,400	$ 2,600

Segment Information - Schedule

Segment Information - Schedule of Selected Information for Each Reportable Segment (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Segment Reporting Information [Line Items]
Consolidated net revenues	$ 541,296	$ 450,977
Operating income (loss)	45,164	17,558
Depreciation and amortization	(23,763)	(25,003)
Stock-based compensation	(1,417)	(470)
Operating expenses	(587,115)	(500,742)
Interest income (expense), net	(55,853)	(56,463)
Gain on extinguishment of debt	221
Income (loss) before income tax (provision) benefit and income (loss) from equity investments	(10,468)	(38,905)
Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating income (loss)	79,332	48,630
Operating Segments [Member] | Clinical [Member]
Segment Reporting Information [Line Items]
Consolidated net revenues	254,859	219,664
Operating income (loss)	42,736	25,649
Operating Segments [Member] | Commercial [Member]
Segment Reporting Information [Line Items]
Consolidated net revenues	290,926	234,546
Operating income (loss)	48,920	31,879
Operating Segments [Member] | Corporate and Other [Member]
Segment Reporting Information [Line Items]
Operating income (loss)	(12,324)	(8,898)
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Consolidated net revenues	(4,489)	(3,233)
Other Unallocated Charges [Member]
Segment Reporting Information [Line Items]
Operating expenses	$ (8,988)	$ (5,599)

Guarantor Financial Informati50

Guarantor Financial Information - Condensed Consolidating Balance Sheet Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 77,113	$ 121,317	$ 38,653	$ 57,059
Restricted cash	2,554	1,607
Accounts receivable, net of allowances for doubtful accounts	328,326	359,081
Unbilled services	261,723	207,465
Prepaid expenses and other current assets	45,059	42,930
Income tax receivable	1,022	1,076
Total current assets	715,797	733,476
Property and equipment, net	139,172	142,032
Goodwill	896,765	895,369
Intangible assets, net	325,919	334,646
Non-current deferred tax assets	10,421	10,032
Other assets	39,721	37,134
Total assets	2,127,795	2,152,689
Current liabilities:
Current portion of capital lease obligations and other financing arrangements	25,296	23,333
Accrued payroll, accounts payable and accrued expenses	318,948	333,726
Income taxes payable	3,829	5,484
Deferred revenue and client advances	246,621	246,656
Total current liabilities	594,694	609,199
Capital lease obligations, net of current portion	45,525	45,258
Long-term debt, net of current portion	2,117,132	2,101,885
Non-current income tax liability	7,567	5,942
Deferred tax liability	79,106	73,360
Other non-current liabilities	66,750	88,153
Total liabilities	2,910,774	2,923,797
Total inVentiv Health, Inc. stockholder’s deficit	(784,977)	(772,736)
Noncontrolling interest	1,998	1,628
Total stockholder’s deficit	(782,979)	(771,108)
Total liabilities and stockholder’s deficit	2,127,795	2,152,689
Eliminations [Member]
Current assets:
Cash and cash equivalents	(87,289)	(82,879)	(86,134)	(52,037)
Intercompany receivables	(1,414,950)	(1,388,167)
Income tax receivable		(104)
Total current assets	(1,502,239)	(1,471,150)
Non-current intercompany receivables	(458,035)	(480,417)
Investment in consolidated subsidiaries	(807,813)	(769,670)
Total assets	(2,768,087)	(2,721,237)
Current liabilities:
Current portion of capital lease obligations and other financing arrangements	(79,229)	(73,282)
Accrued payroll, accounts payable and accrued expenses	(8,060)	(9,597)
Intercompany payables	(1,414,950)	(1,388,167)
Income taxes payable		(104)
Total current liabilities	(1,502,239)	(1,471,150)
Non-current intercompany liabilities	(458,035)	(480,417)
Total liabilities	(1,960,274)	(1,951,567)
Total inVentiv Health, Inc. stockholder’s deficit	(807,813)	(769,670)
Total stockholder’s deficit	(807,813)	(769,670)
Total liabilities and stockholder’s deficit	(2,768,087)	(2,721,237)
Inventiv Health Inc [Member]
Current assets:
Cash and cash equivalents	27,758	55,226	27,622	19,643
Restricted cash	1,716	226
Intercompany receivables	504,621	529,457
Prepaid expenses and other current assets	7,364	8,839
Income tax receivable	26	104
Total current assets	541,485	593,852
Property and equipment, net	21,369	23,227
Other assets	20,331	19,084
Non-current intercompany receivables	429,168	416,161
Investment in consolidated subsidiaries	700,686	676,479
Total assets	1,713,039	1,728,803
Current liabilities:
Current portion of capital lease obligations and other financing arrangements	1,429	1,936
Accrued payroll, accounts payable and accrued expenses	78,168	71,953
Intercompany payables	857,790	820,965
Total current liabilities	937,387	894,854
Long-term debt, net of current portion	1,547,653	1,533,197
Deferred tax liability	74	74
Other non-current liabilities	12,902	38,494
Non-current intercompany liabilities		34,920
Total liabilities	2,498,016	2,501,539
Total inVentiv Health, Inc. stockholder’s deficit	(784,977)	(772,736)
Total stockholder’s deficit	(784,977)	(772,736)
Total liabilities and stockholder’s deficit	1,713,039	1,728,803
Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents				3,439
Accounts receivable, net of allowances for doubtful accounts	266,930	292,548
Unbilled services	223,422	174,070
Intercompany receivables	825,469	840,499
Prepaid expenses and other current assets	19,001	11,401
Total current assets	1,334,822	1,318,518
Property and equipment, net	98,916	101,507
Goodwill	855,317	855,317
Intangible assets, net	319,311	328,239
Other assets	4,330	4,491
Non-current intercompany receivables	28,867	29,235
Investment in consolidated subsidiaries	107,127	93,191
Total assets	2,748,690	2,730,498
Current liabilities:
Current portion of capital lease obligations and other financing arrangements	23,831	21,324
Accrued payroll, accounts payable and accrued expenses	182,536	200,063
Intercompany payables	537,244	542,500
Income taxes payable	449	165
Deferred revenue and client advances	189,789	190,828
Total current liabilities	933,849	954,880
Capital lease obligations, net of current portion	45,512	45,247
Long-term debt, net of current portion	569,479	568,688
Non-current income tax liability	4,807	4,806
Deferred tax liability	77,854	73,047
Other non-current liabilities	31,599	30,896
Non-current intercompany liabilities	429,157	416,260
Total liabilities	2,092,257	2,093,824
Total inVentiv Health, Inc. stockholder’s deficit	656,433	636,674
Total stockholder’s deficit	656,433	636,674
Total liabilities and stockholder’s deficit	2,748,690	2,730,498
Non-Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	136,644	148,970	$ 97,165	$ 86,014
Restricted cash	838	1,381
Accounts receivable, net of allowances for doubtful accounts	61,396	66,533
Unbilled services	38,301	33,395
Intercompany receivables	84,860	18,211
Prepaid expenses and other current assets	18,694	22,690
Income tax receivable	996	1,076
Total current assets	341,729	292,256
Property and equipment, net	18,887	17,298
Goodwill	41,448	40,052
Intangible assets, net	6,608	6,407
Non-current deferred tax assets	10,421	10,032
Other assets	15,060	13,559
Non-current intercompany receivables		35,021
Total assets	434,153	414,625
Current liabilities:
Current portion of capital lease obligations and other financing arrangements	79,265	73,355
Accrued payroll, accounts payable and accrued expenses	66,304	71,307
Intercompany payables	19,916	24,702
Income taxes payable	3,380	5,423
Deferred revenue and client advances	56,832	55,828
Total current liabilities	225,697	230,615
Capital lease obligations, net of current portion	13	11
Non-current income tax liability	2,760	1,136
Deferred tax liability	1,178	239
Other non-current liabilities	22,249	18,763
Non-current intercompany liabilities	28,878	29,237
Total liabilities	280,775	280,001
Total inVentiv Health, Inc. stockholder’s deficit	151,380	132,996
Noncontrolling interest	1,998	1,628
Total stockholder’s deficit	153,378	134,624
Total liabilities and stockholder’s deficit	$ 434,153	$ 414,625

Guarantor Financial Informati51

Guarantor Financial Information - Consolidating Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Condensed Income Statements Captions [Line Items]
Net revenues	$ 541,296	$ 450,977
Reimbursed out-of-pocket expenses	90,983	67,323
Total revenues	632,279	518,300
Operating expenses:
Cost of revenues	372,376	300,505
Reimbursable out-of-pocket expenses	90,983	67,323
Selling, general and administrative expenses	123,756	132,914
Total operating expenses	587,115	500,742
Operating income (loss)	45,164	17,558
Gain on extinguishment of debt	221
Interest income (expense), net	(55,853)	(56,463)
Income (loss) before income tax (provision) benefit and income (loss) from equity investments	(10,468)	(38,905)
Income tax (provision) benefit	(8,176)	(4,528)
Income (loss) before income (loss) from equity investments	(18,644)	(43,433)
Income (loss) from equity investments	5	(1,529)
Net income (loss)	(18,639)	(44,962)
Less: Net (income) loss attributable to the noncontrolling interest	(438)	(123)
Net income (loss) attributable to inVentiv Health, Inc.	(19,077)	(45,085)
Eliminations [Member]
Condensed Income Statements Captions [Line Items]
Net revenues	(7,973)	(5,755)
Reimbursed out-of-pocket expenses	(49)	(76)
Total revenues	(8,022)	(5,831)
Operating expenses:
Cost of revenues	(7,314)	(5,262)
Reimbursable out-of-pocket expenses	(49)	(76)
Selling, general and administrative expenses	(659)	(493)
Total operating expenses	(8,022)	(5,831)
Income (loss) from equity investments	(29,357)	2,463
Net income (loss)	(29,357)	2,463
Net income (loss) attributable to inVentiv Health, Inc.	(29,357)	2,463
Inventiv Health Inc [Member]
Operating expenses:
Selling, general and administrative expenses	21,129	16,087
Allocation of intercompany costs	(13,899)	(9,900)
Total operating expenses	7,230	6,187
Operating income (loss)	(7,230)	(6,187)
Gain on extinguishment of debt	221
Interest income (expense), net	(43,831)	(44,398)
Intercompany interest income (expense)	12,975	11,122
Income (loss) before income tax (provision) benefit and income (loss) from equity investments	(37,865)	(39,463)
Income (loss) before income (loss) from equity investments	(37,865)	(39,463)
Income (loss) from equity investments	18,788	(5,622)
Net income (loss)	(19,077)	(45,085)
Net income (loss) attributable to inVentiv Health, Inc.	(19,077)	(45,085)
Guarantor Subsidiaries [Member]
Condensed Income Statements Captions [Line Items]
Net revenues	419,336	346,981
Reimbursed out-of-pocket expenses	83,818	59,616
Total revenues	503,154	406,597
Operating expenses:
Cost of revenues	300,392	236,463
Reimbursable out-of-pocket expenses	83,818	59,616
Selling, general and administrative expenses	71,369	84,539
Allocation of intercompany costs	10,915	7,944
Total operating expenses	466,494	388,562
Operating income (loss)	36,660	18,035
Interest income (expense), net	(12,277)	(12,169)
Intercompany interest income (expense)	(12,715)	(10,972)
Income (loss) before income tax (provision) benefit and income (loss) from equity investments	11,668	(5,106)
Income tax (provision) benefit	(5,145)	(2,975)
Income (loss) before income (loss) from equity investments	6,523	(8,081)
Income (loss) from equity investments	10,574	1,630
Net income (loss)	17,097	(6,451)
Net income (loss) attributable to inVentiv Health, Inc.	17,097	(6,451)
Non-Guarantor Subsidiaries [Member]
Condensed Income Statements Captions [Line Items]
Net revenues	129,933	109,751
Reimbursed out-of-pocket expenses	7,214	7,783
Total revenues	137,147	117,534
Operating expenses:
Cost of revenues	79,298	69,304
Reimbursable out-of-pocket expenses	7,214	7,783
Selling, general and administrative expenses	31,917	32,781
Allocation of intercompany costs	2,984	1,956
Total operating expenses	121,413	111,824
Operating income (loss)	15,734	5,710
Interest income (expense), net	255	104
Intercompany interest income (expense)	(260)	(150)
Income (loss) before income tax (provision) benefit and income (loss) from equity investments	15,729	5,664
Income tax (provision) benefit	(3,031)	(1,553)
Income (loss) before income (loss) from equity investments	12,698	4,111
Net income (loss)	12,698	4,111
Less: Net (income) loss attributable to the noncontrolling interest	(438)	(123)
Net income (loss) attributable to inVentiv Health, Inc.	$ 12,260	$ 3,988

Guarantor Financial Informati52

Guarantor Financial Information - Consolidating Statement of Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Condensed Statement Of Income Captions [Line Items]
Net Income (loss)	$ (18,639)	$ (44,962)
Other comprehensive income (loss):
Foreign currency translation adjustment	5,419	(5,445)
Total other comprehensive income (loss)	5,419	(5,445)
Total comprehensive income (loss)	(13,220)	(50,407)
Less: Comprehensive (income) loss attributable to the noncontrolling interest	(438)	(123)
Comprehensive income (loss) attributable to inVentiv Health, Inc.	(13,658)	(50,530)
Eliminations [Member]
Condensed Statement Of Income Captions [Line Items]
Net Income (loss)	(29,357)	2,463
Other comprehensive income (loss):
Foreign currency translation adjustment	(8,781)	9,446
Total other comprehensive income (loss)	(8,781)	9,446
Total comprehensive income (loss)	(38,138)	11,909
Comprehensive income (loss) attributable to inVentiv Health, Inc.	(38,138)	11,909
Inventiv Health Inc [Member]
Condensed Statement Of Income Captions [Line Items]
Net Income (loss)	(19,077)	(45,085)
Other comprehensive income (loss):
Foreign currency translation adjustment	5,419	(5,445)
Total other comprehensive income (loss)	5,419	(5,445)
Total comprehensive income (loss)	(13,658)	(50,530)
Comprehensive income (loss) attributable to inVentiv Health, Inc.	(13,658)	(50,530)
Guarantor Subsidiaries [Member]
Condensed Statement Of Income Captions [Line Items]
Net Income (loss)	17,097	(6,451)
Other comprehensive income (loss):
Foreign currency translation adjustment	2,662	(5,435)
Total other comprehensive income (loss)	2,662	(5,435)
Total comprehensive income (loss)	19,759	(11,886)
Comprehensive income (loss) attributable to inVentiv Health, Inc.	19,759	(11,886)
Non-Guarantor Subsidiaries [Member]
Condensed Statement Of Income Captions [Line Items]
Net Income (loss)	12,698	4,111
Other comprehensive income (loss):
Foreign currency translation adjustment	6,119	(4,011)
Total other comprehensive income (loss)	6,119	(4,011)
Total comprehensive income (loss)	18,817	100
Less: Comprehensive (income) loss attributable to the noncontrolling interest	(438)	(123)
Comprehensive income (loss) attributable to inVentiv Health, Inc.	$ 18,379	$ (23)

Guarantor Financial Informati53

Guarantor Financial Information - Condensed Consolidating Statement of Cash Flows (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net cash provided by (used in) operating activities	$ (9,620)	$ 2,151
Cash flows from investing activities:
Purchases of property and equipment	(6,170)	(9,799)
Proceeds from vehicle sales and rebates on vehicle leases	3,979	3,093
Other, net	(966)	(238)
Net cash provided by (used in) investing activities	(3,157)	(6,944)
Cash flows from financing activities:
Repayments on capital leases and other financing arrangements	(8,907)	(8,924)
Borrowings under line of credit		17,000
Repayment on line of credit		(17,000)
Repurchase of Notes	(22,790)
Payment on installment note and contingent consideration related to acquisition	(2,174)	(1,917)
Other, net	396	25
Net cash provided by (used in) financing activities	(33,475)	(10,816)
Effects of foreign currency exchange rate changes on cash	2,048	(2,797)
Net increase (decrease) in cash and cash equivalents	(44,204)	(18,406)
Cash and cash equivalents, beginning of period	121,317	57,059
Cash and cash equivalents, end of period	77,113	38,653
Eliminations [Member]
Cash flows from operating activities:
Net cash provided by (used in) operating activities	(8,060)	(6,385)
Cash flows from investing activities:
Intercompany transfers	(55,925)	(51,656)
Net cash provided by (used in) investing activities	(55,925)	(51,656)
Cash flows from financing activities:
Intercompany transfers	59,575	23,944
Net cash provided by (used in) financing activities	59,575	23,944
Net increase (decrease) in cash and cash equivalents	(4,410)	(34,097)
Cash and cash equivalents, beginning of period	(82,879)	(52,037)
Cash and cash equivalents, end of period	(87,289)	(86,134)
Inventiv Health Inc [Member]
Cash flows from operating activities:
Net cash provided by (used in) operating activities	(36,631)	(37,855)
Cash flows from investing activities:
Purchases of property and equipment	(1,811)	(2,777)
Intercompany transfers	37,937	51,656
Other, net	(1,491)	(238)
Net cash provided by (used in) investing activities	34,635	48,641
Cash flows from financing activities:
Repayments on capital leases and other financing arrangements	(972)	(983)
Borrowings under line of credit		17,000
Repayment on line of credit		(17,000)
Repurchase of Notes	(22,790)
Payment on installment note and contingent consideration related to acquisition	(2,174)	(1,917)
Other, net	464	93
Net cash provided by (used in) financing activities	(25,472)	(2,807)
Net increase (decrease) in cash and cash equivalents	(27,468)	7,979
Cash and cash equivalents, beginning of period	55,226	19,643
Cash and cash equivalents, end of period	27,758	27,622
Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash provided by (used in) operating activities	15,585	37,407
Cash flows from investing activities:
Purchases of property and equipment	(1,401)	(5,199)
Proceeds from vehicle sales and rebates on vehicle leases	3,979	3,093
Intercompany transfers	17,988
Net cash provided by (used in) investing activities	20,566	(2,106)
Cash flows from financing activities:
Repayments on capital leases and other financing arrangements	(7,896)	(7,816)
Intercompany transfers	(28,255)	(30,924)
Net cash provided by (used in) financing activities	(36,151)	(38,740)
Net increase (decrease) in cash and cash equivalents		(3,439)
Cash and cash equivalents, beginning of period		3,439
Non-Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash provided by (used in) operating activities	19,486	8,984
Cash flows from investing activities:
Purchases of property and equipment	(2,958)	(1,823)
Other, net	525
Net cash provided by (used in) investing activities	(2,433)	(1,823)
Cash flows from financing activities:
Repayments on capital leases and other financing arrangements	(39)	(125)
Intercompany transfers	(31,320)	6,980
Other, net	(68)	(68)
Net cash provided by (used in) financing activities	(31,427)	6,787
Effects of foreign currency exchange rate changes on cash	2,048	(2,797)
Net increase (decrease) in cash and cash equivalents	(12,326)	11,151
Cash and cash equivalents, beginning of period	148,970	86,014
Cash and cash equivalents, end of period	$ 136,644	$ 97,165